60 Degrees Pharmaceuticals (SXTP) 10-Q20 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2023	Nov. 20, 2023
Document Information Line Items
Entity Registrant Name	60 DEGREES PHARMACEUTICALS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		5,799,535
Amendment Flag	false
Entity Central Index Key	0001946563
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41719
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2406880
Entity Address, Address Line One	1025 Connecticut Avenue
Entity Address, Address Line Two	NW Suite 1000
Entity Address, State or Province	WA
Entity Address, City or Town	Washington
Entity Address, Postal Zip Code	20036
City Area Code	(202)
Local Phone Number	327-5422
Entity Interactive Data Current	Yes
Common Stock, par value $0.0001 per share
Document Information Line Items
Trading Symbol	SXTP
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Warrants, each warrant to purchase one share of Common Stock
Document Information Line Items
Trading Symbol	SXTPW
Title of 12(b) Security	Warrants, each warrant to purchase one share of Common Stock
Security Exchange Name	NASDAQ

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 2,218,540	$ 264,865
Accounts Receivable	138,009	45,965
Prepaid and Other	5,939,927	200,967
Deferred Offering Costs		68,629
Inventory, net	598,319	518,578
Total Current Assets	8,894,795	1,099,004
Property and Equipment, net	3,836	21,300
Other Assets:
Right of Use Asset	26,534	12,647
Intangible Assets, net	225,047	164,255
Total Other Assets	251,581	176,902
Total Assets	9,150,212	1,297,206
Current Liabilities:
Accounts Payable and Accrued Expenses	271,602	758,668
Lease Liability	26,800	13,000
Deferred Compensation		325,000
Related Party Notes, net (including accrued interest)		195,097
Debenture		4,276,609
SBA EIDL (including accrued interest)	8,772	2,750
Promissory Notes (including accrued interest)		16,855,887
Derivative Liabilities	2,174,194	1,129,840
Derivative Liabilities - Related Parties		364,360
Total Current Liabilities:	2,481,368	23,921,211
Long-Term Liabilities:
Deferred Compensation		255,000
SBA EIDL (including accrued interest)	152,594	160,272
Promissory Notes (including accrued interest)		1,109,783
Total Long-Term Liabilities	152,594	1,525,055
Total Liabilities	2,633,962	25,446,266
Commitments and Contingencies
SHAREHOLDERS’ EQUITY (DEFICIT):
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; 78,803 issued and outstanding as of September 30, 2023 and 0 as of December 31, 2022, respectively (Note 6)	9,858,040
Class A common stock, $0.0001 par value, 150,000,000 shares authorized; 5,799,535 and 2,386,009 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively (Note 6)	580	239
Additional Paid-in Capital	27,182,915	5,164,461
Accumulated Other Comprehensive Income	81,386	73,708
Accumulated Deficit	(30,568,566)	(28,815,148)
60P Shareholders’ Equity (Deficit):	6,554,355	(23,576,740)
Noncontrolling interest	(38,105)	(572,320)
Total Shareholders’ Equity (Deficit)	6,516,250	(24,149,060)
Total Liabilities and Shareholders’ Equity (Deficit)	$ 9,150,212	$ 1,297,206

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	78,803	0
Preferred stock, shares outstanding	78,803	0
Class A common stock [Member]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	5,799,535	2,386,009
Common stock, shares outstanding	5,799,535	2,386,009

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Product Revenues – net of Discounts and Rebates	$ 51,188	$ 168,185	$ 127,892	$ 260,382
Cost of Revenues	71,196	92,281	328,293	269,535
Gross Revenue (Loss)	(20,008)	75,904	(200,401)	(9,153)
Research Revenues	75,566	150,262	82,974	259,669
Net Revenue (Loss)	55,558	226,166	(117,427)	250,516
Operating Expenses:
Research and Development	263,703	27,655	591,569	322,106
General and Administrative Expenses	1,313,617	413,627	2,551,426	994,157
Total Operating Expenses	1,577,320	441,282	3,142,995	1,316,263
Loss from Operations	(1,521,762)	(215,116)	(3,260,422)	(1,065,747)
Interest Expense	(40,106)	(1,215,978)	(2,281,191)	(2,883,714)
Derivative Expense			(399,725)	(504,613)
Change in Fair Value of Derivative Liabilities	92,490	(22,495)	95,324	(23,496)
Loss on Debt Extinguishment	(391,593)		(1,231,480)
Change in Fair Value of Promissory Note	6,105,066		5,379,269
Other Income (Expense), net	(70,490)	3,172	(69,169)	(29,810)
Total Interest and Other Income (Expense), net	5,695,367	(1,235,301)	1,493,028	(3,441,633)
Income (Loss) from Operations before Provision for Income Taxes	4,173,605	(1,450,417)	(1,767,394)	(4,507,380)
Provision for Income Taxes	63	250	189	750
Net Income (Loss) including Noncontrolling Interest	4,173,542	(1,450,667)	(1,767,583)	(4,508,130)
Net Loss – Noncontrolling Interest	(9,656)	(3,172)	(14,165)	(1,454)
Net Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc.	4,183,198	(1,447,495)	(1,753,418)	(4,506,676)
Comprehensive Income (Loss)
Net Income (Loss)	4,173,542	(1,450,667)	(1,767,583)	(4,508,130)
Unrealized Foreign Currency Translation Gain (Loss)	9,342	(6,417)	7,678	(20,850)
Total Comprehensive Income (Loss)	4,182,884	(1,457,084)	(1,759,905)	(4,528,980)
Net Loss – Noncontrolling Interest	(9,656)	(3,172)	(14,165)	(1,454)
Unrealized Foreign Currency Translation Loss from Noncontrolling Interest		(544)		(544)
Comprehensive Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc.	4,192,540	(1,453,368)	(1,745,740)	(4,526,982)
Cumulative dividends on Series A Preferred Stock	(101,538)		(101,538)
Net Income (Loss) - attributed to common stockholders	$ 4,091,002	$ (1,453,368)	$ (1,847,278)	$ (4,526,982)
Net Income (Loss) per Common Share:
Net Loss per common share Basic (in Dollars per share)	$ 0.77	$ (0.61)	$ (0.55)	$ (1.92)
Weighted average number of common shares outstanding
Weighted average number of common shares outstanding Basic (in Shares)	5,319,255	2,386,009	3,344,843	2,361,569

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Loss per common share Diluted	$ 0.77	$ (0.61)	$ (0.55)	$ (1.92)
Weighted average number of common shares outstanding Diluted	5,319,255	2,386,009	3,344,843	2,361,569

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders’ and Members’ Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock	Members’ Equity	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Shareholders’ Equity (Deficit) Attributable to 60P	Noncontrolling Interest on Shareholders	Total
Balance at Dec. 31, 2021		$ 4,979,365			$ (22,633,428)	$ 75,835	$ (17,578,228)	$ (576,256)	$ (18,154,484)
Balance (in Shares) at Dec. 31, 2021		18,855,165
Net Foreign Translation Gain (Loss)						96,556	96,556		96,556
Net Income (Loss)					(912,282)		(912,282)	4,835	(907,447)
Balance at Mar. 31, 2022		$ 4,979,365			(23,545,710)	172,391	(18,393,954)	(571,421)	(18,965,375)
Balance (in Shares) at Mar. 31, 2022		18,855,165
Balance at Dec. 31, 2021		$ 4,979,365			(22,633,428)	75,835	(17,578,228)	(576,256)	(18,154,484)
Balance (in Shares) at Dec. 31, 2021		18,855,165
Share-based compensation expense
Net Income (Loss)									(4,508,130)
Balance at Sep. 30, 2022			$ 239	5,164,461	(27,140,104)	55,529	(21,919,875)	(578,254)	(22,498,129)
Balance (in Shares) at Sep. 30, 2022			2,386,009
Balance at Mar. 31, 2022		$ 4,979,365			(23,545,710)	172,391	(18,393,954)	(571,421)	(18,965,375)
Balance (in Shares) at Mar. 31, 2022		18,855,165
Business Combination: June 1, 2022 (60P LLC into 60P, Inc.)		$ (4,979,365)	$ 235	4,979,130
Business Combination: June 1, 2022 (60P LLC into 60P, Inc.) (in Shares)		(18,855,165)	2,348,942
Issuance of Common Stock			$ 4	185,331			185,335		185,335
Issuance of Common Stock (in Shares)			37,067
Net Foreign Translation Gain (Loss)						(110,989)	(110,989)		(110,989)
Net Income (Loss)					(2,146,899)		(2,146,899)	(3,117)	(2,150,016)
Balance at Jun. 30, 2022			$ 239	5,164,461	(25,692,609)	61,402	(20,466,507)	(574,538)	(21,041,045)
Balance (in Shares) at Jun. 30, 2022			2,386,009
Net Foreign Translation Gain (Loss)						(5,873)	(5,873)	(544)	(6,417)
Net Income (Loss)					(1,447,495)		(1,447,495)	(3,172)	(1,450,667)
Balance at Sep. 30, 2022			$ 239	5,164,461	(27,140,104)	55,529	(21,919,875)	(578,254)	(22,498,129)
Balance (in Shares) at Sep. 30, 2022			2,386,009
Balance at Dec. 31, 2022			$ 239	5,164,461	(28,815,148)	73,708	(23,576,740)	(572,320)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022			2,386,009
Issuance of Common Stock			$ 144	5,378,764			5,378,908		5,378,908
Issuance of Common Stock (in Shares)			1,443,000
Cancellation of common stock			$ (145)	145
Cancellation of common stock (in Shares)			(1,451,000)
Net Foreign Translation Gain (Loss)						(1,290)	(1,290)		(1,290)
Net Income (Loss)					(2,600,061)		(2,600,061)	2,527	(2,597,534)
Balance at Mar. 31, 2023			$ 238	10,543,370	(31,415,209)	72,418	(20,799,183)	(569,793)	(21,368,976)
Balance (in Shares) at Mar. 31, 2023			2,378,009
Balance at Dec. 31, 2022			$ 239	5,164,461	(28,815,148)	73,708	(23,576,740)	(572,320)	(24,149,060)
Balance (in Shares) at Dec. 31, 2022			2,386,009
Share-based compensation expense									670,871
Net Income (Loss)									(1,767,583)
Balance at Sep. 30, 2023	$ 9,858,040		$ 580	27,182,915	(30,568,566)	81,386	6,554,355	(38,105)	6,516,250
Balance (in Shares) at Sep. 30, 2023	78,803		5,799,535
Balance at Mar. 31, 2023			$ 238	10,543,370	(31,415,209)	72,418	(20,799,183)	(569,793)	(21,368,976)
Balance (in Shares) at Mar. 31, 2023			2,378,009
Net Foreign Translation Gain (Loss)						(374)	(374)		(374)
Net Income (Loss)					(3,336,555)		(3,336,555)	(7,036)	(3,343,591)
Balance at Jun. 30, 2023			$ 238	10,543,370	(34,751,764)	72,044	(24,136,112)	(576,829)	(24,712,941)
Balance (in Shares) at Jun. 30, 2023			2,378,009
Net Foreign Translation Gain (Loss)						9,342	9,342		9,342
Issuance of common stock for payment of deferred compensation			$ 3	154,997			155,000		155,000
Issuance of common stock for payment of deferred compensation (in Shares)			29,245
Conversion of debt into common stock upon initial public offering			$ 171	7,989,427			7,989,598		7,989,598
Conversion of debt into common stock upon initial public offering (in Shares)			1,707,179
Conversion of debt into Series A Preferred Stock upon initial public offering	$ 10,128,500						10,128,500		10,128,500
Conversion of debt into Series A Preferred Stock upon initial public offering (in Shares)	80,965
Reclassification of liability-classified warrants to equity-classified				838,748			838,748		838,748
Issuance of common stock pursuant to IPO, net of underwriting discounts and offering costs of $1,266,740			$ 141	6,235,135			6,235,276		6,235,276
Issuance of common stock pursuant to IPO, net of underwriting discounts and offering costs of $1,266,740 (in Shares)			1,415,095
Issuance of common stock upon exercise of warrants			$ 18	1,131,753			1,131,771		1,131,771
Issuance of common stock upon exercise of warrants (in Shares)			184,447
Voluntary conversion of Series A Preferred Stock into common stock	$ (270,460)		$ 5	270,455
Voluntary conversion of Series A Preferred Stock into common stock (in Shares)	(2,162)		45,560
Issuance of common stock pursuant to share-based compensation awards			$ 4	187,196			187,200		187,200
Issuance of common stock pursuant to share-based compensation awards (in Shares)			40,000
Share-based compensation expense				271,066			271,066		271,066
Prepaid share-based compensation				109,148			109,148		109,148
Contribution from noncontrolling interest				(548,380)			(548,380)	548,380
Net Income (Loss)					4,183,198		4,183,198	(9,656)	4,173,542
Balance at Sep. 30, 2023	$ 9,858,040		$ 580	$ 27,182,915	$ (30,568,566)	$ 81,386	$ 6,554,355	$ (38,105)	$ 6,516,250
Balance (in Shares) at Sep. 30, 2023	78,803		5,799,535

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Shareholders’ and Members’ Equity (Deficit) (Unaudited) (Parentheticals)	3 Months Ended
	Sep. 30, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of underwriting discounts and offering costs	$ 1,266,740

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,767,583)	$ (4,508,130)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation	19,287	20,747
Amortization	20,606	2,783
Amortization of Debt Discount	669,148	821,154
Amortization of ROU Asset	37,035	33,848
Amortization of Note Issuance Costs	67,728
Amortization of Capitalized Services	690,173
Stock-based Compensation	670,871
Loss on Debt Extinguishment	1,231,480
Change in Fair Value of Derivative Liabilities	(95,324)	23,496
Derivative Expense	399,725	504,613
Change in Fair Value of Promissory Note	(5,379,269)
Inventory Reserve	(139,946)
Changes in Operating Assets and Liabilities:
Accounts Receivable	(92,044)	(48,679)
Prepaid and Other	(1,512,578)	58,083
Inventory	60,205	(36,415)
Accounts Payable and Accrued Liabilities	(489,337)	(36,199)
Accrued Interest	1,267,703	2,055,810
Reduction of Lease Liability	(37,122)	(34,271)
Deferred Compensation	(100,000)	199,157
Net Cash Used in Operating Activities	(4,479,242)	(944,003)
CASH FLOWS FROM INVESTING ACTIVITIES
Capitalization of Patents	(29,220)	(1,488)
Purchases of Property and Equipment	(1,823)
Acquisition of Intangibles	(18,283)
Net Cash Used in Investing Activities	(49,326)	(1,488)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of Deferred Offering Costs	(150,420)
Net proceeds from IPO and Over-Allotment	6,454,325
Proceeds from the exercise of warrants	1,131,771
Proceeds from issuance of Common Stock		185,335
Proceeds from Notes Payable	650,000	800,000
Proceeds from Notes Payable - Related Parties		305,000
Repayment of Notes Payable	(1,611,111)
Advances from Related Parties	250,000
Repayment of Related Party Advances	(250,000)
Net Cash Provided by Financing Activities	6,474,565	1,290,335
Foreign Currency Translation Gain (Loss)	7,678	(20,850)
Change in Cash	1,953,675	323,994
Cash—Beginning of Period	264,865	115,399
Cash—End of Period	2,218,540	439,393
NONCASH INVESTING/FINANCING ACTIVITIES
Conversion of Debt into Common Stock	7,989,598
Conversion of Debt into Series A Preferred Stock	10,128,500
Conversion of Series A Preferred Stock into Common Stock	270,460
Common Stock Issued as Prepayment for Services	4,916,556
Additions to ROU Assets for Lease Renewal	50,922
Additions to Lease Liabilities for Lease Renewal	50,570
Conversion of 60P LLC Member Units to Common Stock		4,979,365
Debt Discount Recorded in Connection with Derivative Liabilities	650,000	1,105,000
Stock Issued for Payment of Deferred Compensation	480,000
Stock Issued for Acquisition of Intangibles	33,895
Fair Value of Warrants Issued to Underwriters	301,416
Reclassification of Liability-classified Warrants to Equity-classified	$ 838,748

Nature of Operations

Nature of Operations	9 Months Ended
Nature of Operations	Sep. 30, 2023
Nature of Operations [Abstract]
NATURE OF OPERATIONS	1. NATURE OF OPERATIONS 60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiaries (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses payable by the Company (the “IPO”). Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants are immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028). The Company granted the underwriters a 45-day over-allotment option to purchase up to 212,265 shares of the Company’s common stock at a price of $5.28 per share and/or 212,265 Tradeable Warrants at a price of $0.01 per Tradeable Warrant and/or 212,265 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination thereof (the “Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 100,644 Tradeable Warrants and 100,644 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 84,906 shares of the Company’s common stock, at an exercise price of $5.83 per share, which is equal to 110% of the offering price per Unit (the “Representative Warrants”). The Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023. See Note 6 for further details. Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued. In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern. Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as a business combination or other profitable investment may be achieved.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in our opinion, include all adjustments consisting of normal recurring adjustments and accruals necessary for a fair presentation of our consolidated condensed balance sheets, consolidated condensed statements of operations and other comprehensive income (loss), consolidated condensed statements of shareholders’ and member’s equity (deficit) and consolidated condensed statements of cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements for the years ended December 31, 2022 and 2021 and related notes thereto as contained in the Company’s Registration Statement. Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Registration Statement have been omitted. Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a contribution from noncontrolling interest in the accompanying consolidated condensed statement of shareholders’ and members’ equity (deficit). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset. Gain/Loss on Debt Extinguishment Gain or loss on debt extinguishment is generally recorded upon an extinguishment of a debt instrument or the conversion of certain of the Company’s convertible debt determined to have variable share settlement features. Gain or loss on extinguishment of debt is calculated as the difference between the reacquisition price and net carrying amount of the debt, which includes unamortized debt issuance costs and the fair value of any related derivative instruments. In the case of debt instruments for which the fair value option has been elected, the net carrying value is equal to its fair value on the date of extinguishment and no gain or loss is recognized. Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of September 30, 2023, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date. Equity-Classified Warrants The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, the Representative Warrants, and the Bridge Warrants (following the IPO, see Note 6) as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding. IPO and Over-Allotment The Over-Allotment option granted to the underwriters was evaluated in accordance with the guidance in ASC 480 and ASC 815 and was determined to meet all of the criteria for equity classification. The Company allocated the proceeds from the sale of the IPO units (net of offering costs incurred at closing and deferred offering costs incurred prior to the IPO) between the common stock, the Tradeable Warrants, the Non-tradeable Warrants, and the Over-Allotment, using the relative fair value method. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. 100% of receivables as of September 30, 2023, consisting of two significant customers at 78% and 22%, are outstanding from significant customers. At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were outstanding from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers (100% for the three months ended September 30, 2022 consisting of three significant customers at 48%, 43%, and 9%). For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28% (100% for the nine months ended September 30, 2022, consisting of three customers at 65%, 29%, and 6% respectively). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of September 30, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company. The terms of the preferred share conversion with Knight Therapeutics currently limits the Company’s ability to access additional credit without their consent. Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $263,703 and $591,569 in research and development costs expense during the three and nine months ended September 30, 2023, respectively ($182,655 and $477,106 for the three and nine months ended September 30, 2022, respectively). During the nine months ended September 30, 2023, the Company issued 525,000 common stock shares and 405,000 common stock shares as share-based payments to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., respectively, in exchange for research and development services to be rendered to the Company in the future. The agreements with these nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state security laws, the nonemployees can sell the received equity instruments. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of one year. Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. 718, Compensation–Stock Compensation. At September 30, 2023, the Company recorded $2,834,148 current unamortized deferred prepaid research and development costs ($0 at December 31, 2022). Current unamortized deferred prepaid research and development costs are presented as a component of Prepaid and Other on the accompanying consolidated condensed balance sheets. Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the consolidated balance sheets and any change in fair value unrelated to credit risk is recorded in other income in the consolidated statements of operations. Changes in fair value related to credit risk are recognized in other comprehensive income. As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 8 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at September 30, 2023, and December 31, 2022 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 9 for more information on Derivative Liabilities. Liabilities measured at fair value at September 30, 2023 and December 31, 2022 are as follows: September 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ - $ - Derivative Liabilities - - 2,174,194 2,174,194 Total $ - $ - $ 2,174,194 $ 2,174,194 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200 Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the group and the statement of financial position and equity of the company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized in other income. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended September 30, Nine Months Ended September 30, As of Currency 2023 2022 2023 2022 September 30, December 31, 1 AUD = 0.6545 USD 0.6837 USD 0.6688 USD 0.7074 USD 0.6428 USD 0.6805 USD 1 SGD = NA NA NA 1.0150 AUD* NA 1.0230 AUD* *Through 4/30/2022 (account closure date) Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive income (loss), shareholders’ and members’ equity (deficit), or cash flows. Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 11. The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur. The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized straight-line over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the equity instruments when they are granted. The corresponding cost is recognized as an immediate expense or a prepaid asset depending on the specific facts and circumstances of the agreement with the nonemployee. During the nine months ended September 30, 2023 and 2022, 513,000 and 0 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. 120,000 and 100,000 of the common stock shares issued during the nine months ended September 30, 2023 were issued to Trevally, LLC and Carmel, Milazzo & Feil LLP, respectively. Before March 31, 2024, Trevally, LLC is expected to provide castanopsermine, a stable starting material to support the manufacture of good manufacturing grade (GMP)-grade celgosivir for clinical studies. Carmel, Milazzo & Feil LLP is expected to provide legal services before March 31, 2024. As of September 30, 2023, the unamortized balance of prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $1,063,235 ($0 at December 31, 2022), which is reported in Prepaid and Other on the Consolidated Condensed Balance Sheets. Net Income (Loss) per Common Share Net Income (Loss) per Common Share is computed by dividing net income or loss by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as a reduction to net income (loss) in determining basic and diluted net earnings (loss) attributable to common stockholders. For periods in which a loss is reported, diluted net loss per common share is the same as basic net loss per common share for those periods. Securities that could potentially dilute basic earnings per share in the future but were excluded from diluted calculation because the effect was anti-dilutive. The potential dilutive securities include: common stock warrants, stock options and unvested restricted stock units granted under the 2022 Plan. Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through November 20, 2023, which is the date the financial statements were issued. See Note 13. Recently Issued and Adopted Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on these consolidated condensed financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on the Company’s consolidated condensed financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This latter standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company’s adoption of this standard in 2022 did not have a material effect on the Company’s consolidated condensed financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements.

Inventory

Inventory	9 Months Ended
Inventory	Sep. 30, 2023
Inventory [Abstract]
INVENTORY	3. INVENTORY Inventory consists of the following major classes: September 30, December 31, Raw Material (API) $ 350,362 $ 397,487 Packaging 73,391 97,486 Finished Goods 108,208 183,943 Clinical Trial Supplies 149,812 63,062 Total Inventory 681,773 741,978 Reserve for Expiring Inventory (83,454 ) (223,400 ) Inventory, net $ 598,319 $ 518,578

Property and Equipment

Property and Equipment	9 Months Ended
Property and Equipment	Sep. 30, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT As of September 30, 2023 and December 31, 2022, Property and Equipment consists of: September 30, December 31, Lab Equipment $ 132,911 $ 132,911 Computer Equipment 14,084 12,261 Furniture 3,030 3,030 Property and Equipment, at Cost 150,025 148,202 Accumulated depreciation (146,189 ) (126,902 ) Property and Equipment, Net $ 3,836 $ 21,300 Depreciation expenses for Property and Equipment for the nine months ended September 30, 2023 and 2022 were in the amount of $19,287 and $20,747, respectively ($5,485 and $6,901 for the three months ended September 30, 2023 and 2022, respectively).

Intangible Assets

Intangible Assets	9 Months Ended
Intangible Assets	Sep. 30, 2023
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS As of September 30, 2023 and December 31, 2022, Intangible Assets consist of: September 30, December 31, Patents $ 174,833 $ 145,613 Website Development Costs 79,248 27,070 Intangible Assets, at Cost 254,081 172,683 Accumulated Amortization (29,034 ) (8,428 ) Intangible Assets, Net $ 225,047 $ 164,255 During the three months ended September 30, 2023 and 2022, the Company capitalized website development or related costs of $12,283 and $0, respectively ($52,178 and $0 for the nine months ended September 30, 2023 and 2022, respectively), in connection with the upgrade and enhancement of functionality of the corporate website at www.60-p.com. Amortization expense for the nine months ended September 30, 2023, and 2022 was in the amount of $20,606 and $2,783, respectively ($7,414 and $1,831 for the three months ended September 30, 2023 and 2022, respectively). The following table summarizes the estimated future amortization expense for our patents and website development costs as of September 30, 2023: Period Patents Website 2023 (remaining three months) $ 1,670 $ 6,604 2024 6,681 26,416 2025 6,681 23,303 2026 6,681 3,974 Thereafter 55,656 - Total $ 77,369 $ 60,297 The Company additionally has $83,808 in capitalized patent expenses that will be amortizable as the patents they are associated with are awarded.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2023
Stockholders' Equity [Abstract]
STOCKHOLDERS’ EQUITY	6. STOCKHOLDERS’ EQUITY On June 1, 2022, 60P LLC entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. (the “Merger”). The value of each outstanding member’s membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost basis equal to $5 per share. Pursuant to the Certificate of Incorporation of 60 Degrees Pharmaceuticals, Inc., the Company’s authorized shares consist of (a) 150,000,000 shares of common stock, par value $0.0001 per share and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share, of which 80,965 have been designated as Series A Non-Voting Convertible Preferred Stock (“Series A Preferred Stock”). As of September 30, 2023, 5,799,535 shares of Common Stock and 78,803 shares of Series A Preferred Stock are issued and outstanding. Common Stock On June 30, 2022 the Company issued 37,067 shares of common stock to its Chief Executive Officer for $185,335 at a purchase price of $5 per share. In January and March 2023, the Board of Directors, with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 192,101 shares of common stock issued to Tyrone Miller and 1,258,899 shares of common stock issued to the Geoffrey S. Dow Revocable Trust to allow the Company to issue new shares to vendors in exchange for valuable services to be provided for use in the Company’s operations. The cancelled shares represented approximately 61% of the issued and outstanding shares as of December 31, 2022. In January and March 2023, the Company issued a total of 1,443,000 shares of common stock to certain vendors as payment for services rendered or to be provided to the Company. In connection with the closing of the Company’s IPO as discussed in Note 1, the Company issued common stock as follows: ● As a result of the effectiveness of the Registration Statement on July 11, 2023, the Company issued a total of 40,000 restricted shares of common stock to the following directors and in the amounts listed: (i) Stephen Toovey (10,000 restricted shares of common stock), (ii) Charles Allen (10,000 restricted shares of common stock), (iii) Paul Field (10,000 restricted shares of common stock) and (iv) Cheryl Xu (10,000 restricted shares of common stock), by virtue of the terms of the agreements discussed in Note 12. ● On July 13, 2023, the Company issued 31,447 shares of common stock upon the exercise of 31,447 Bridge Warrants (as defined below). ● On July 14, 2023, the IPO closed, and the Company issued 1,415,095 shares of common stock from the sale of units at a price of $5.30 per unit, generating $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated IPO expenses. As a result of the completion of the IPO and as required under the terms of the respective agreements, on July 14, 2023: o The Company issued an aggregate of 383,908 shares of common stock upon conversion of the 2022 and 2023 Bridge Notes and the Related Party Notes described in Note 8. o The Company issued 29,245 shares of common stock to BioIntelect as deferred equity compensation valued in the amount of $155,000. o The Company issued 214,934 shares of common stock upon conversion of the Xu Yu Note, including the Amendment described in Note 8. o The Company issued 1,108,337 shares of common stock to Knight upon conversion of the cumulative outstanding principal as of March 31, 2022 at the conversion price detailed in Note 8 (representing 19.9% of our outstanding common stock after giving effect to the IPO). ● On July 14, 2023 the Company issued 60,000 shares of common stock upon the exercise of 60,000 Non-tradeable Warrants. ● On July 17, 2023, the Company issued 93,000 shares of common stock upon the exercise of 93,000 Tradeable Warrants. ● On July 25, 2023, the Company issued 45,560 shares of common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock. Common Stock Warrants In May 2022 and May 2023, in connection with the issuance of the Related Party Notes and the 2022 and 2023 Bridge Notes as described in Note 8, the Company issued five-year warrants to each of the noteholders with an exercise price dependent on the IPO price (collectively, the “Bridge Warrants”). The number of shares issuable upon exercise of the warrants was contingent on the number of shares issued upon conversion of the notes following the Company’s IPO. As of the closing of the Company’s IPO, the Bridge Warrants became exercisable into an aggregate of 231,917 shares of the Company’s common stock, 79,926 of which have an exercise price of $4.77 (90% of the IPO price), and 151,991 with an exercise price of $5.83 (110% of the IPO Price). Prior to the IPO, the Bridge Warrants were classified as derivative liabilities in accordance with the provisions of ASC 815 and were carried at their respective fair values. (See Note 9). In connection with the IPO, the terms of the Bridge Warrants became fixed. The Company determined the event resulted in equity classification for the Bridge Warrants and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified the warrants to additional paid-in capital. On July 12, 2023, the Company executed a Warrant Agent Agreement with Equity Stock Transfer, LLC, acting as warrant agent for the IPO, which sets forth the procedures for registering, transferring and exercising the Tradeable warrants and Non-tradeable warrants issued in connection with the IPO. The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, and the Representative Warrants (defined in Note 1) as equity-classified financial instruments. There were no equity-classified warrants issued or outstanding prior to the Company’s IPO. The following table summarizes the activity for the Company’s equity-classified warrants for the three months ended September 30, 2023: Number of Weighted Weighted Total outstanding, June 30, 2023 - $ - - Reclassified from derivative liabilities 231,917 5.46 4.15 Granted 3,116,384 6.22 5.00 Exercised (184,447 ) 6.14 5.00 Forfeited - - - Expired - - - Total outstanding, September 30, 2023 3,163,854 $ 6.17 4.73 Total exercisable, September 30, 2023 3,163,854 $ 6.17 4.73 There were no warrant exercises, forfeitures, or expirations prior to the IPO. During the three months ended September 30, 2023, the Company received aggregate cash proceeds of $1,131,771 upon the exercise of 31,447 Bridge Warrants, 60,000 Non-tradeable Warrants, and 93,000 Tradeable Warrants. Series A Preferred Stock As described in Note 8, as a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the Company converted the entirety of the accumulated interest on the Convertible Knight Loan as of March 31, 2022 into 80,965 shares of Series A Preferred Stock at the Conversion Price detailed below. On July 25, 2023, the Company converted 2,162 shares of Series A Preferred Stock into 45,560 shares of Common Stock at the conversion rate detailed below. No The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Voting Rights Dividends Liquidation Rights – Conversion Rights

Deferred Compensation

Deferred Compensation	9 Months Ended
Deferred Compensation	Sep. 30, 2023
Deferred Compensation [Abstract]
DEFERRED COMPENSATION	7. DEFERRED COMPENSATION In 2020, the Company received consulting services from Biointelect Pty Ltd. of Australia (“Biointelect”) with a value of $100,000, which is payable contingent upon a future capital raise and is non-interest bearing. On May 5, 2022, the Company agreed to modify their contract with Biointelect. Previously, Biointelect potentially could earn $60,000 in deferred cash compensation and $400,000 in warrants in connection with a fundraise and other services provided. As the Company considered this compensation unlikely, it agreed to restructure by increasing the cash component to $100,000, tying $155,000 in equity compensation to an IPO or future qualifying transaction while leaving $245,000 in equity compensation with the original triggering events. As a result of the completion of the IPO and as required under the terms of the agreement with BioIntelect, the Company issued 29,245 shares of common stock to BioIntelect as deferred equity compensation and remitted payment in cash of $100,000 in full satisfaction of its obligations with respect to the services provided. Also in 2020, the Company entered into an agreement with Latham Biopharma for contingent compensation. On June 17, 2022 the Company and Latham Biopharma agreed to convert the $57,198 of deferred compensation that was earned and due and $12,500 of accrued expenses into a 100% contingent deferred compensation amount of $38,900 in cash and $60,000 in common shares of the Company if, within the next five years the Company nets at least $10,000,000 in an IPO or any private financing that secures the retirement and/or conversion to equity of all secured debt excluding the loans advanced by the Small Business Administration. Then before the year ended December 31, 2022, the Company and Latham Biopharma initiated an agreement that converted the entire deferred compensation into 65,000 shares valued at $5 per share. As of December 31, 2022, the Company recognized a contingent liability related to the subsequent agreement of $325,000. On January 11, 2023, the Company issued 65,000 shares to Latham Biopharma in full satisfaction of its obligations with respect to the services provided.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2023
Debt [Abstract]
DEBT	8. DEBT Knight Therapeutics, Inc. On December 27, 2019 the Company restructured its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc. (‘Knight’), into a note for the principal amount of $6,309,823 and accrued interest of $4,160,918 and a debenture of $3,483,851 (collectively, the ‘Knight Loan’). The Knight Loan had a maturity date of December 31, 2023. The principal and accrued interest portion of the Knight Loan bear an annual interest rate of 15%, compounded quarterly, whereas the debenture had a 9% interest rate until April 23, 2023 at which point interest ceased accruing. As of December 31, 2022, the aggregate outstanding balance of the Knight Loan was $20,596,595. In January 2023, the Company and Knight executed the Knight Debt Conversion Agreement, pursuant to which the parties agreed to add a conversion feature to the cumulative outstanding Knight Loans, which was accounted for as a debt extinguishment, described further below. Note, including Amendment On October 11, 2017 the Company issued a promissory note (“Note”) with an individual investor in the amount of $750,000. The Note matures 60 days after the Knight Loans are repaid. The Note originally bore an interest rate of 5% from inception for the first six months and 10% per annum thereafter both compounded quarterly. On December 11, 2022, the Company and the individual investor amended the Note (“the Amendment”). The Amendment added a provision to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the Company consummates an IPO. The Amendment also provides the lender the option to convert the outstanding principal and accumulated interest through March 31, 2022 into equity shares of the Company at the maturity date, which option shall expire 30 days after maturity. Cumulative interest after March 31, 2022 will be forfeited should the lender elect to convert the Note into equity. At the Amendment date, the Company recorded a discount of $120,683 related to the excess fair value of the Note and incurred costs with third parties directly related to the Amendment of $1,767, which are being amortized over the remaining life of the debt using the effective interest method. Amortization of the discount on the Note for the three months ended September 30, 2023 and 2022 was $3,869 and $0, respectively ($52,628 and $0 for the nine months ended September 30, 2023 and 2022, respectively). Interest expense related to the Note, for the three months ended September 30, 2023 and 2022 was $4,944 and $29,429, respectively ($66,558 and $85,242 for the nine months ended September 30, 2023 and 2022, respectively). As a result of the completion of the IPO and as required under the terms of the Note, including the Amendment, the outstanding principal and accrued interest through March 31, 2022 converted to 214,934 shares of our common stock at a conversion rate equal to the IPO price, in full satisfaction of the outstanding debt obligation. The Company recognized a debt extinguishment gain of $223,077 upon conversion, representing the difference (i) the reacquisition price, consisting of the fair value of the common shares issued, and (ii) the net carrying value of the debt, inclusive of unamortized discounts and issuance costs, on the date of conversion. Promissory notes are summarized as follows at September 30, 2023: Knight Note, Bridge Total Promissory Notes (including accrued interest) $ - $ - $ - $ - Promissory Notes (including accrued interest) - - - - Less Current Maturities - - - - Long Term Promissory Notes $ - $ - $ - $ - Promissory notes are summarized as follows at December 31, 2022: Knight Note, Bridge Total Promissory Notes (including accrued interest) $ 16,319,986 $ 1,109,783 $ 535,901 $ 17,965,670 Less Current Maturities 16,319,986 - 535,901 16,855,887 Long Term Promissory Notes $ - $ 1,109,783 $ - $ 1,109,783 Convertible Promissory Notes and Warrants During May 2022, the Company executed promissory notes having a face amount of $888,889. The notes contained an original issue discount of 10% ($88,889) and debt issuance costs of $91,436, resulting in net proceeds of $708,564. These notes bear interest at 10% with a default interest rate of 15% and are unsecured. The notes were due at the earlier of one year from the issuance date or the closing of an IPO (the “2022 Bridge Notes”). In connection with the issuance of the 2022 Bridge Notes, the Company agreed to issue common stock to each noteholder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these note holders were entitled to receive five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price (See Note 6). In May 2023, the maturity date for the 2022 Bridge Notes was extended for an additional two months. In exchange for extension of the maturity date, the Company agreed to additional cash payments totaling $22,222 due to the holders of the 2022 Bridge Notes at maturity (the “Extension Payments”). During May 2023, the Company executed promissory notes having an aggregate face amount of $722,222. The notes contained an original issue discount of 10% ($72,222) and the Company incurred debt issuance costs of $95,000, resulting in net proceeds to the Company of $555,000. These notes bear interest at 10% with a default interest rate of 15% and are unsecured. The notes were due at the earlier of one-year from the issuance date or the closing of an IPO (the “2023 Bridge Notes”). In connection with the issuance of the 2023 Bridge Notes, the Company also agreed to issue common stock to each note holder equivalent to 100% of the face amount of the note divided by the IPO price per share. Additionally, each of these noteholders were entitled to receive five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 110% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Bridge Notes and the warrants and concluded that such instruments qualify for treatment as derivative liabilities under ASC 815 and require bifurcation from the host contract. Derivative liabilities are carried at fair value at each balance sheet date, and any changes in fair value are recognized in the accompanying consolidated condensed statement of operations and comprehensive income (loss). See Note 9 for further details. As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 303,982 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488 for the outstanding principal, accrued interest and Extension Payments (2022 Bridge Notes only), in full settlement of the outstanding debt obligations. The embedded derivative liability (conversion feature) was marked to market on the settlement date, and the Company recognized a debt extinguishment loss of $614,670 upon settlement, representing the difference between (i) the reacquisition price, consisting of cash and shares, and (ii) the net carrying value of the debt including associated derivative liabilities on the date of conversion. Related Party Notes During May 2022, the Company executed convertible promissory notes with the Company’s Chief Executive Officer and a family member related to the Chief Executive Officer, having an aggregate face amount of $338,889. The notes contain an original issue discount of 10% ($33,888) and debt issuance costs of $34,289, resulting in net proceeds of $270,711. These notes bear interest at 6% with a default interest rate of 15% and are unsecured. The notes were due at the earlier of one-year (1) from the issuance date or the closing of an IPO (the “Related Party Notes”). In May 2023, the maturity date for the Related Party Notes was extended for an additional two months. In exchange for extension of the maturity date, the Company agreed to additional cash payments totaling $8,472 due to the holders of the Related Party Notes at maturity (the “Extension Payments”). Upon the closing of the IPO, these notes were mandatorily convertible at a conversion rate determined at a 20% discount to the IPO price, discussed further below. Additionally, each of these note holders received five-year (5) fully vested warrants upon the closing of the IPO, with an exercise price of 90% of the IPO price. The Company performed an evaluation of the conversion features embedded in the Related Party Notes and the warrants and concluded that such instruments qualified for treatment as derivative liabilities under ASC 815 and required bifurcation from the host contract. See Note 9 for further details. Bridge Notes and Related Party Notes are summarized as follows at September 30, 2023 and December 31, 2022: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 1 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 2 2 2 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes - - - Less: unamortized debt discount - - - Add: accrued interest on promissory notes - - - Balance - September 30, 2023 $ - $ - $ - 1 earlier of 1 year from date of issuance or closing of IPO. 2 see discussion above for (a) and (b) For the nine months ended September 30, 2023 and 2022, the Company recorded amortization of debt discounts, including issuance costs, of $670,550 and $453,063, respectively. As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 79,926 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding accrued interest and Extension Payments. The Company recognized a final mark to market adjustment of the embedded derivative liability (conversion feature), and as a result, no gain or loss was recognized on the debt extinguishment. Knight Debt Conversion On January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight’s debt in the event of an IPO. Key points of this agreement are as follows: ● The Parties agreed to fix Knight’s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original debt would resume including any interest earned after March 31, 2022. ● The Parties agreed to convert the fixed principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount equal to the offering price of the common stock in the IPO discounted by 15%, rounding up for fractional shares, in a number of common shares up to 19.9% of the Company’s outstanding common stock after giving effect of the IPO; (ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells Arakoda™ or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda™ or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January 21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda™ to include COVID-19 indications as well as malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith). ● The parties agreed to convert the accrued interest into that number of shares of a new class of preferred stock (the “Preferred Stock”) by dividing the fixed accumulated interest by $100.00, then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the shares of common stock in the initial public offering and (2) the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the Company’s sole discretion. Notwithstanding the foregoing, the Preferred Stock shall not be converted into shares of common stock if as a result of such conversion Knight will own 19.9% or more of our outstanding common stock. ● In addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the Closing or the conversion or redemption in full of the Preferred Stock, Company shall pay Lender a royalty equal to 3.5% of the Company’s net sales (the “Royalty”), where “Net Sales” has the same meaning as in the Company’s lic ense agreement with the U.S. Army for tafenoquine. Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight at the end of each calendar quarter. The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) business days after the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed following the above instructions, on the first calendar quarter in which the Qualified IPO takes place and will cover the sales for the period from January 1, 2022 until the end of said calendar quarter. The Company evaluated the January 9, 2023 exchange agreement in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. Upon extinguishment, the Company recorded a loss upon extinguishment in the amount of $839,887 and elected to recognize the new debt under the ASC 825 fair value option until it is settled. A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 $ 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 $ 23,539,996 Fair value - mark to market adjustment (6,105,066 ) Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at September 30, 2023 $ - As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,106,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment. The Company performed an evaluation of the contingent payment features and concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The future Royalty payment due to Knight was determined to be an embedded component of the Series A Preferred Stock, however is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense within cost of sales as sales are made. Debenture On April 24, 2019, 60P entered into the Knight debenture of $3,000,000 with an original issue discount of $2,100,000, which was being amortized using the effective interest method. The Company subsequently restructured the Knight Loans, including the debenture, pursuant to the Knight Debt Conversion Agreement (see above). $13,696 of the original issue discount was amortized to interest expense in 2023 prior to the amendment ($368,091 during the nine months ended September 30, 2022) and the unamortized original issue discount at September 30, 2023 was $0 ($279,061 at December 31, 2022) as a result of the debt conversion (discussed above), which was accounted for as a debt extinguishment. The Knight debenture as of September 30, 2023 and December 31, 2022 consisted of the following: September 30, December 31, Original Debenture $ - $ 3,000,000 Unamortized debt discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609 SBA COVID-19 EIDL On May 14, 2020, the Company received COVID-19 EIDL lending from the Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly basis. The Company was committed to make $731 monthly payments first due June 4, 2021. On March 31, 2021, the SBA announced the deferment period has been extended an additional eighteen months. Thus, the Company was first obligated to start making interest payments of $731 on November 4, 2022. The balance as of September 30, 2023 is $161,366 ($163,022 at December 31, 2022). The current maturity at September 30, 2023 is $8,772 and the long-term liability is $152,594 ($2,750 and $160,272 at December 31, 2022, respectively). The current future payment obligations of the principal are as follows: Period Principal Payments 2023 (remaining three months) $ - 2024 - 2025 - 2026 - 2027 2,804 Thereafter 147,196 Total $ 150,000 Due to the deferral, the Company is expected to make a balloon payment of $32,383 to be due on 10/12/2050. Related Party Advances In March 2023, the Company received a $200,000 short term advance from the Geoffrey S. Dow Revocable Trust. In April 2023, the Company received $50,000 as a short-term advance from management. The Geoffrey S. Dow Revocable Trust contributed $23,000 and Tyrone Miller contributed $27,000. On May 11, 2023, these short term advances were refunded in full for an aggregate amount of $250,000.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
Derivative Liabilities	Sep. 30, 2023
Derivative Liabilities [Abstract]
DERIVATIVE LIABILITIES	9. DERIVATIVE LIABILITIES In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities. As discussed in Note 8 above, certain of the Company’s bridge shares, warrants and convertible notes (containing an embedded conversion feature) were previously accounted for as derivative liabilities. The bridge shares and related conversion features were derecognized upon conversion on the date of the IPO. The Bridge Warrants (defined in Note 6) were previously accounted for as derivative liabilities as there was an unknown exercise price and number of shares associated with each instrument. In connection with the IPO, the terms of the Bridge Warrants became fixed. The Company determined the event resulted in equity classification for the Bridge Warrants. Accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified the warrants to additional paid-in capital on the IPO date. As of September 30, 2023, derivative liabilities consist of the contingent milestone payment due to Knight upon a future sale of Arakoda™ or a Change of Control (See Note 8). The valuation of the contingent milestone payment includes significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. In connection with the valuation of the Company’s derivative liabilities related to the 2022 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 24, 2022) of $1,483,888. As the fair value of the derivative liabilities exceeded the net proceeds received of $979,275, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the OID and debt issuance costs, as detailed in Note 8), which required the excess to be recorded as a derivative expense. Derivative expense recorded during the three and nine months ended September 30, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 In connection with the valuation of the Company’s derivative liabilities related to the 2023 Bridge Notes and warrants, the Company determined a fair value on the commitment date (May 8, 2023) of $954,725. As the fair value of the derivative liabilities exceeded the net proceeds received of $555,000, the Company recorded a debt discount at the maximum amount allowed (the face amount of the debt less the OID and debt issuance costs detailed in Note 8) and recorded the excess as derivative expense. Derivative expense recorded during the three and nine months ended September 30, 2023 is summarized as follows: Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at September 30, 2023 and December 31, 2022: Bridge Shares Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) - 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ - $ 1,499,334 Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 - (7,968 ) Derivative liabilities - June 30, 2023 $ 1,528,426 $ 837,293 $ 80,372 $ - $ 2,446,091 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 57,052 57,052 Derivative liabilities - September 30, 2023 $ - $ - $ - $ 2,174,194 $ 2,174,194 A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at September 30, 2022 and December 31, 2021: Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 664 2,932 (2,595 ) 1,001 Derivative liabilities - June 30, 2022 $ 824,351 $ 567,939 $ 92,599 $ 1,484,889 Fair value - mark to market adjustment 1,352 25,869 (4,726 ) 22,495 Derivative liabilities - September 30, 2022 $ 825,703 $ 593,808 $ 87,873 $ 1,507,384 Changes in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying consolidated condensed statements of operations and comprehensive income (loss). During the nine months ended September 30, 2023, the Company recorded a net change in the fair of derivative liabilities of ($95,324). From the commitment date of May 8, 2022 to September 30, 2022, the Company recorded a net change in the fair value of derivative liabilities of $23,496. On the respective commitment dates (Day 1 valuation), the fair value of the Company’s potential future issuances of common stock related to common stock issued with promissory notes, warrants and embedded conversion features in convertible promissory notes was established with an estimate using the Monte Carlo Simulation Model to compute fair value. The Monte Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years, expected dividend yield, and risk-free rate. In addition, the valuation model considered the probability of the occurrence or nonoccurrence of an IPO within the terms of liability-classified financial instruments, as an IPO could potentially impact the settlement. At each subsequent reporting period, we have remeasured the fair value of liability-classified bridge shares, warrants and embedded conversion features in convertible promissory notes using the Monte Carlo simulation. The assumptions used to perform the Monte-Carlo Simulation as of the respective commitment dates, as well as December 31, 2022 were as follows: Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00 Volatility 115.1 % 99.7 % Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00 Risk-free interest rate 4.80 % 2.76% - 2.84 % Dividend yield 0 % 0 % IPO probability (prior to note maturity date) 95 % 95 % Mark to Market December 31, 2022 Stock price $ 5.00 Volatility 101.9 % Expected term (in years) - Notes 0.39 - 0.41 Expected term (in years) - Warrants 4.39 Risk-free interest rate 4.06 % Dividend yield 0 % IPO probability (prior to note maturity date) 95 %

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Taxes [Abstract]
INCOME TAXES	10. INCOME TAXES The Company did not record a federal income tax provision or benefit for each of the three and nine months ended September 30, 2023 and 2022 due to losses. The Company recorded a provision for income taxes for DC of $63 and $189 for the three and nine months ended September 30, 2023, respectively, thereby reflecting the minimum statutory tax due ($250 and $750 for the three and nine months ended September 30, 2022, respectively).

Share-Based Compensation

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	11. SHARE-BASED COMPENSATION On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. As of September 30, 2023, the maximum shares available under the 2022 Plan is equal to 238,601. Stock Grants On July 11, 2023, the Company recognized $187,196 of share-based compensation expense upon the issuance of 40,000 shares of common stock to the Company’s Board of Directors, by virtue of the terms of the agreements described in Note 12, which is reflected in general and administrative expenses in the consolidated condensed statement of operations. Stock Options The Company grants stock options to employees, non-employees, and Directors with exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a term of five years from the grant date and vest over periods ranging from one to five years. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model. The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2023: 2023 Weighted-average grant date fair value $ 3.42 Risk-free interest rate 4.25% - 4.33 % Expected volatility 105.0% - 110.0 % Expected term (years) 3.18 - 3.76 Expected dividend yield 0.00 % Upon the Closing of the IPO on July 12, 2023, the Company granted an aggregate of 607,924 stock options to directors and executives, with a weighted average exercise price of $4.75. There were no stock options granted, issued, or outstanding prior to the IPO. For the three and nine months ended September 30, 2023, the Company recognized $233,728 of compensation expense related to stock option awards ($0 for the three and nine months ended September 30, 2022). Restricted Stock Units Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. Upon the Closing of the IPO on July 12, 2023, the Company granted an aggregate of 32,000 RSUs to directors of the Company. No RSUs were granted, vested, or outstanding prior to the IPO. For the three and nine month periods ended September 30, 2023, the Company recognized $37,338 of compensation expense related to the vesting of 8,000 RSUs ($0 and 0 shares, respectively, for the three and nine months ended September 30, 2022). These shares are excluded from the number of shares outstanding at September 30, 2023 as the shares have not yet been legally issued.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	12. COMMITMENTS AND CONTINGENCIES Operating Lease On February 3, 2016, and subsequently amended, the Company entered into the lease agreement with CXI Corp to rent business premises. In January 2023, the lease was extended for an additional twelve-month term until March 31, 2024. The Company applies ASC 842 to its operating leases, which are reflected on the consolidated condensed balance sheets within Right of Use (ROU) Asset and the related current and non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from lease agreement. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectation regarding the terms. Variable lease costs such as common area maintenance, property taxes and insurance are expensed as incurred. Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease are as follows: Undiscounted Discount rate 15.00 % 2023 (remaining three months) $ 13,992 2024 13,992 Thereafter - Total undiscounted minimum future payments 27,984 Imputed interest (1,184 ) Total operating lease payments 26,800 Short-term lease liabilities 26,800 Long-term lease liabilities $ - Other information related to our operating lease is as follows: September 30, Weighted average remaining lease term (in years) 0.50 Weighted average discount rate 15.00 % Operating lease costs were in the amount of $13,859 and $12,974 for the three months ended September 30, 2023, and September 30, 2022, respectively ($41,225 and $38,921 for the nine months ended September 30, 2023, and September 30, 2022, respectively). Board of Directors In November and December 2022, the Company signed agreements with four director nominees (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which come into effect on the date the Company’s Registration Statement is declared effective. As described in Note 1, the Company’s Registration Statement was declared effective on July 11, 2023. Each director is entitled to receive cash compensation of $11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee chair (Allen) will receive an additional $2,000 per quarter. On July 11, 2023, each director received (i) a one-off issuance of 10,000 shares of common stock, (ii) a fully vested, non-qualified option to purchase 9,434 shares of common stock at an exercise price of $5.30 per share, (iii) a non-qualified option to purchase 7,547 shares of common stock at an exercise price of $5.30 per share, which vests 100% one year from the date of grant, and (iv) restricted stock units covering 8,000 shares of the Company’s common stock which vest in equal quarterly installments over one year from the date of grant. See Note 11 for further details. Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. Contingent Compensation Prior to 2015 the Company agreed with certain vendors, advisors and employees to deferred compensation that expires on December 31, 2023. The net amount of these contingent payments is $43,581. The Company does not anticipate the trigger for these payments to be reached prior to expiration. Following the Company’s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note 8, the Company is obligated to pay Knight a contingent milestone payment of $10 million if the Company sells Arakoda™ or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note 9). Litigation, Claims and Assessments From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of September 30, 2023, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company has evaluated subsequent events through November 20, 2023, which is the date the financial statements were issued. On October 6, 2023, the Company’s Board of Directors decided that its subsidiary, 60P Australia Pty Ltd., will not re-submit its investigational new drug (“IND”) application for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression. The decision was in response to recent comments received from the U.S. Food and Drug Administration (“FDA”). As a result, the Company expects a return of the deposited funds from the contract research organization engaged for the suspended trial of approximately $820,000, of which $419,755 was received on November 9, 2023. The Company decided it will instead prepare to conduct a Phase IIA study of tafenoquine in hospitalized babesiosis patients. On November 1, 2023, the Company submitted a request for a Type C meeting with FDA under its malaria IND 129656. That meeting is scheduled for January 15, 2024. On November 2, 2023, the Company received a letter from The Nasdaq Capital Market stating that for the 30 consecutive business days ending on November 1, 2023, the Company’s common stock had not maintained the minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market. The Company was provided an initial period of 180 calendar days, or until April 30, 2024, to regain compliance. If the Company cannot regain compliance during the compliance period or any subsequently granted compliance period, the common stock and warrants of the Company may be subject to delisting. There have been no other events or transactions during this time which would have a material effect on these financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements of 60P and its subsidiaries are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). These financial statements are unaudited and, in our opinion, include all adjustments consisting of normal recurring adjustments and accruals necessary for a fair presentation of our consolidated condensed balance sheets, consolidated condensed statements of operations and other comprehensive income (loss), consolidated condensed statements of shareholders’ and member’s equity (deficit) and consolidated condensed statements of cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements for the years ended December 31, 2022 and 2021 and related notes thereto as contained in the Company’s Registration Statement. Certain information and footnote disclosures that would substantially duplicate the disclosures contained in the Registration Statement have been omitted.
Principles of Consolidation and Noncontrolling Interest	Principles of Consolidation and Noncontrolling Interest The Company’s consolidated condensed financial statements include the financial statements of its majority owned subsidiary 60P Australia Pty Ltd, as well as the financial statements of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was closed via dissolution as of March 31, 2022. 60P Singapore Pty Lte was originally set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner, and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain. For entities that are consolidated, but not 100% owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income or loss and corresponding equity that is not owned by us is included in Noncontrolling Interest in the consolidated financial statements. On August 2, 2023, Geoffrey Dow assigned his interest in 60P Australia Pty Ltd, of 904,436 common shares to the Company for no consideration, thereby increasing the proportional ownership of 60P, Inc. in 60P Australia Pty Ltd from 87.53% to 96.61%. The purpose of this assignment was to eliminate the related party conflict associated with Geoffrey Dow’s ultimate beneficial ownership in 60P Australia Pty Ltd being greater than that of other 60P, Inc. shareholders. The increase in the Company’s proportional interest is reflected as a contribution from noncontrolling interest in the accompanying consolidated condensed statement of shareholders’ and members’ equity (deficit).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, and valuation allowance for the deferred tax asset.
Gain/Loss on Debt Extinguishment	Gain/Loss on Debt Extinguishment Gain or loss on debt extinguishment is generally recorded upon an extinguishment of a debt instrument or the conversion of certain of the Company’s convertible debt determined to have variable share settlement features. Gain or loss on extinguishment of debt is calculated as the difference between the reacquisition price and net carrying amount of the debt, which includes unamortized debt issuance costs and the fair value of any related derivative instruments. In the case of debt instruments for which the fair value option has been elected, the net carrying value is equal to its fair value on the date of extinguishment and no gain or loss is recognized.
Derivative Liabilities	Derivative Liabilities The Company assesses the classification of its derivative financial instruments each reporting period, which formerly consisted of bridge shares, convertible notes payable, and certain warrants, and determined that such instruments qualified for treatment as derivative liabilities as they met the criteria for liability classification under ASC 815. As of September 30, 2023, the Company’s derivative financial instruments consist of contingent payment arrangements. The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 480, (“ASC 480”), Distinguishing Liabilities from Equity and FASB ASC Topic No. 815, Derivatives and Hedging (“ASC 815”). Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model to determine the fair value of these instruments. Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any. Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date.
Equity-Classified Warrants	Equity-Classified Warrants The Company accounts for the Tradeable Warrants, the Non-tradeable Warrants, the Representative Warrants, and the Bridge Warrants (following the IPO, see Note 6) as equity-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.
IPO and Over-Allotment	IPO and Over-Allotment The Over-Allotment option granted to the underwriters was evaluated in accordance with the guidance in ASC 480 and ASC 815 and was determined to meet all of the criteria for equity classification. The Company allocated the proceeds from the sale of the IPO units (net of offering costs incurred at closing and deferred offering costs incurred prior to the IPO) between the common stock, the Tradeable Warrants, the Non-tradeable Warrants, and the Over-Allotment, using the relative fair value method.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and borrowings. Significant customers represent any customer whose business makes up 10% of receivables or revenues. 100% of receivables as of September 30, 2023, consisting of two significant customers at 78% and 22%, are outstanding from significant customers. At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were outstanding from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers (100% for the three months ended September 30, 2022 consisting of three significant customers at 48%, 43%, and 9%). For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28% (100% for the nine months ended September 30, 2022, consisting of three customers at 65%, 29%, and 6% respectively). Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant. Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”). As of September 30, 2023, 0% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, previously the senior secured lender and also a publicly traded Canadian company. The terms of the preferred share conversion with Knight Therapeutics currently limits the Company’s ability to access additional credit without their consent.
Research and Development	Research and Development Costs The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepaid research and development costs are deferred and amortized over the service period as the services are provided. The Company recorded $263,703 and $591,569 in research and development costs expense during the three and nine months ended September 30, 2023, respectively ($182,655 and $477,106 for the three and nine months ended September 30, 2022, respectively). During the nine months ended September 30, 2023, the Company issued 525,000 common stock shares and 405,000 common stock shares as share-based payments to two nonemployees, Kentucky Technology Inc. and Florida State University Research Fund, Inc., respectively, in exchange for research and development services to be rendered to the Company in the future. The agreements with these nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state security laws, the nonemployees can sell the received equity instruments. Kentucky Technology Inc. is expected to render research and development services to identify a combination drug partner for tafenoquine over a period of one year. Florida State University Research Fund, Inc. is expected to render research and development services related to development of celgosivir over a period of up to five years. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. 718, Compensation–Stock Compensation. At September 30, 2023, the Company recorded $2,834,148 current unamortized deferred prepaid research and development costs ($0 at December 31, 2022). Current unamortized deferred prepaid research and development costs are presented as a component of Prepaid and Other on the accompanying consolidated condensed balance sheets.
Fair Value of Financial Instruments and the Fair Value Option (“FVO”)	Fair Value of Financial Instruments and the Fair Value Option (“FVO”) The carrying value of the Company’s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2 - Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3 - Unobservable inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the consolidated balance sheets and any change in fair value unrelated to credit risk is recorded in other income in the consolidated statements of operations. Changes in fair value related to credit risk are recognized in other comprehensive income. As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 8 for more information on the extinguishment of the Promissory Notes. The Company’s financial instruments recorded at fair value on a recurring basis at September 30, 2023, and December 31, 2022 include Derivative Liabilities, which are carried at fair value based on Level 3 inputs. See Note 9 for more information on Derivative Liabilities. Liabilities measured at fair value at September 30, 2023 and December 31, 2022 are as follows: September 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ - $ - Derivative Liabilities - - 2,174,194 2,174,194 Total $ - $ - $ 2,174,194 $ 2,174,194 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200
Foreign Currency Transactions and Translation	Foreign Currency Transactions and Translation The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated financial statements of the group and the statement of financial position and equity of the company are presented in US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements. For the purpose of presenting consolidated financial statements, the assets and liabilities of the group’s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized in other income. Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended September 30, Nine Months Ended September 30, As of Currency 2023 2022 2023 2022 September 30, December 31, 1 AUD = 0.6545 USD 0.6837 USD 0.6688 USD 0.7074 USD 0.6428 USD 0.6805 USD 1 SGD = NA NA NA 1.0150 AUD* NA 1.0230 AUD* *Through 4/30/2022 (account closure date)
Reclassifications	Reclassifications Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive income (loss), shareholders’ and members’ equity (deficit), or cash flows.
Share-Based Payments	Share-Based Payments On November 22, 2022, the Company adopted the 2022 Equity Incentive Plan also referred to as (“2022 Plan”). The 2022 Plan and related share-based awards are discussed more fully in Note 11. The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur. The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company’s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, Share-Based Payment Compensation expense for restricted stock units (“RSUs”) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company’s common stock on the grant date multiplied by the number of shares awarded. For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized straight-line over the remaining service period. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the equity instruments when they are granted. The corresponding cost is recognized as an immediate expense or a prepaid asset depending on the specific facts and circumstances of the agreement with the nonemployee. During the nine months ended September 30, 2023 and 2022, 513,000 and 0 common stock shares, respectively, were issued as fully vested, nonforfeitable equity instruments to nonemployees. The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments. 120,000 and 100,000 of the common stock shares issued during the nine months ended September 30, 2023 were issued to Trevally, LLC and Carmel, Milazzo & Feil LLP, respectively. Before March 31, 2024, Trevally, LLC is expected to provide castanopsermine, a stable starting material to support the manufacture of good manufacturing grade (GMP)-grade celgosivir for clinical studies. Carmel, Milazzo & Feil LLP is expected to provide legal services before March 31, 2024. As of September 30, 2023, the unamortized balance of prepaid assets related to these share-based payments for which the services are expected to be rendered within one year is $1,063,235 ($0 at December 31, 2022), which is reported in Prepaid and Other on the Consolidated Condensed Balance Sheets.
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share Net Income (Loss) per Common Share is computed by dividing net income or loss by the weighted average number of common shares outstanding during each period. For the purposes of calculating the weighted average number of common shares outstanding for periods prior to the Merger (See Note 6), each of 60P LLC’s outstanding membership units as of June 1, 2022 have been retrospectively adjusted for the equivalent number of common shares issued pursuant to the Merger. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as a reduction to net income (loss) in determining basic and diluted net earnings (loss) attributable to common stockholders. For periods in which a loss is reported, diluted net loss per common share is the same as basic net loss per common share for those periods. Securities that could potentially dilute basic earnings per share in the future but were excluded from diluted calculation because the effect was anti-dilutive. The potential dilutive securities include: common stock warrants, stock options and unvested restricted stock units granted under the 2022 Plan.
Related Parties	Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Subsequent Events	Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through November 20, 2023, which is the date the financial statements were issued. See Note 13.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements From time to time, the FASB issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on these consolidated condensed financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from U.S. GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on the Company’s consolidated condensed financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This latter standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company’s adoption of this standard in 2022 did not have a material effect on the Company’s consolidated condensed financial statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company’s adoption of ASU 2021-08 did not have an effect on its consolidated condensed financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Liabilities Measured at Fair Value	Liabilities measured at fair value at September 30, 2023 and December 31, 2022 are as follows: September 30, 2023 Level 1 Level 2 Level 3 Total Liabilities: Promissory Notes (including accrued interest), at fair value $ - $ - $ - $ - Derivative Liabilities - - 2,174,194 2,174,194 Total $ - $ - $ 2,174,194 $ 2,174,194 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities: Derivative Liabilities $ - $ - $ 1,494,200 $ 1,494,200 Total $ - $ - $ 1,494,200 $ 1,494,200
Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements	Exchange rates along with historical rates used in these financial statements are as follows: Average Exchange Rate Three Months Ended September 30, Nine Months Ended September 30, As of Currency 2023 2022 2023 2022 September 30, December 31, 1 AUD = 0.6545 USD 0.6837 USD 0.6688 USD 0.7074 USD 0.6428 USD 0.6805 USD 1 SGD = NA NA NA 1.0150 AUD* NA 1.0230 AUD* *Through 4/30/2022 (account closure date)

Inventory (Tables)

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Sep. 30, 2023
Inventory [Abstract]
Schedule of Inventory	Inventory consists of the following major classes: September 30, December 31, Raw Material (API) $ 350,362 $ 397,487 Packaging 73,391 97,486 Finished Goods 108,208 183,943 Clinical Trial Supplies 149,812 63,062 Total Inventory 681,773 741,978 Reserve for Expiring Inventory (83,454 ) (223,400 ) Inventory, net $ 598,319 $ 518,578

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
Property and Equipment (Tables)	Sep. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	As of September 30, 2023 and December 31, 2022, Property and Equipment consists of: September 30, December 31, Lab Equipment $ 132,911 $ 132,911 Computer Equipment 14,084 12,261 Furniture 3,030 3,030 Property and Equipment, at Cost 150,025 148,202 Accumulated depreciation (146,189 ) (126,902 ) Property and Equipment, Net $ 3,836 $ 21,300

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
Intangible Assets (Tables)	Sep. 30, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	As of September 30, 2023 and December 31, 2022, Intangible Assets consist of: September 30, December 31, Patents $ 174,833 $ 145,613 Website Development Costs 79,248 27,070 Intangible Assets, at Cost 254,081 172,683 Accumulated Amortization (29,034 ) (8,428 ) Intangible Assets, Net $ 225,047 $ 164,255
Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	The following table summarizes the estimated future amortization expense for our patents and website development costs as of September 30, 2023: Period Patents Website 2023 (remaining three months) $ 1,670 $ 6,604 2024 6,681 26,416 2025 6,681 23,303 2026 6,681 3,974 Thereafter 55,656 - Total $ 77,369 $ 60,297

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2023
Stockholders' Equity [Abstract]
Schedule of Equity Classified Warrants	There were no equity-classified warrants issued or outstanding prior to the Company’s IPO. The following table summarizes the activity for the Company’s equity-classified warrants for the three months ended September 30, 2023: Number of Weighted Weighted Total outstanding, June 30, 2023 - $ - - Reclassified from derivative liabilities 231,917 5.46 4.15 Granted 3,116,384 6.22 5.00 Exercised (184,447 ) 6.14 5.00 Forfeited - - - Expired - - - Total outstanding, September 30, 2023 3,163,854 $ 6.17 4.73 Total exercisable, September 30, 2023 3,163,854 $ 6.17 4.73

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2023
Debt [Abstract]
Schedule of Promissory Notes	Promissory notes are summarized as follows at September 30, 2023: Knight Note, Bridge Total Promissory Notes (including accrued interest) $ - $ - $ - $ - Promissory Notes (including accrued interest) - - - - Less Current Maturities - - - - Long Term Promissory Notes $ - $ - $ - $ - Knight Note, Bridge Total Promissory Notes (including accrued interest) $ 16,319,986 $ 1,109,783 $ 535,901 $ 17,965,670 Less Current Maturities 16,319,986 - 535,901 16,855,887 Long Term Promissory Notes $ - $ 1,109,783 $ - $ 1,109,783
Schedule of Bridge Notes and Related Party Notes	Bridge Notes and Related Party Notes are summarized as follows at September 30, 2023 and December 31, 2022: 2022 Bridge Related Party 2023 Bridge Issuance date of promissory notes May 2022 May 2022 May 2023 Maturity date of promissory notes 1 1 1 Interest rate 10 % 6 % 10 % Default interest rate 15 % 15 % 15 % Collateral Unsecured Unsecured Unsecured Conversion rate 2 2 2 Face amount of notes $ 888,889 $ 338,889 $ - Less: unamortized debt discount (407,555 ) (155,443 ) - Add: accrued interest on promissory notes 54,567 11,651 - Balance - December 31, 2022 $ 535,901 $ 195,097 $ - Face amount of notes - - - Less: unamortized debt discount - - - Add: accrued interest on promissory notes - - - Balance - September 30, 2023 $ - $ - $ - 1 earlier of 1 year from date of issuance or closing of IPO. 2 see discussion above for (a) and (b)
Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note	A reconciliation of the beginning and ending balances for the Convertible Knight Note, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the three and nine months ended September 30, 2023: Convertible Promissory Notes, at fair value at December 31, 2022 $ - Fair value at modification date - January 9, 2023 21,520,650 Fair value - mark to market adjustment (339,052 ) Accrued interest recognized 634,243 Promissory Notes, at fair value at March 31, 2023 $ 21,815,841 Fair value - mark to market adjustment 1,064,849 Accrued interest recognized 659,306 Promissory Notes, at fair value at June 30, 2023 $ 23,539,996 Fair value - mark to market adjustment (6,105,066 ) Extinguishment of Promissory Notes (17,434,930 ) Promissory Notes, at fair value at September 30, 2023 $ -
Schedule of the Knight Debenture	The Knight debenture as of September 30, 2023 and December 31, 2022 consisted of the following: September 30, December 31, Original Debenture $ - $ 3,000,000 Unamortized debt discount - (279,061 ) Debenture Prior to Accumulated Interest - 2,720,939 Accumulated Interest - 1,555,670 Debenture $ - $ 4,276,609
Schedule of the Current Future Payment Obligations	The current future payment obligations of the principal are as follows: Period Principal Payments 2023 (remaining three months) $ - 2024 - 2025 - 2026 - 2027 2,804 Thereafter 147,196 Total $ 150,000

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
Derivative Liabilities (Tables)	Sep. 30, 2023
Derivative Liabilities [Abstract]
Schedule of Derivative Expense	Derivative expense recorded during the three and nine months ended September 30, 2022 is summarized as follows: Commitment Date May 24, Fair value of derivative liabilities $ 1,483,888 Less: face amount of debt (979,275 ) Derivative expense $ 504,613 Commitment Date May 8, Fair value of derivative liabilities $ 954,725 Less: face amount of debt (555,000 ) Derivative expense $ 399,725
Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis	A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows at September 30, 2023 and December 31, 2022: Bridge Shares Warrants Convertible Contingent Total Derivative liabilities - December 31, 2022 $ 834,352 $ 578,164 $ 81,684 $ - $ 1,494,200 Fair value - mark to market adjustment 4,902 1,689 (1,457 ) - 5,134 Derivative liabilities - March 31, 2023 $ 839,254 $ 579,853 $ 80,227 $ - $ 1,499,334 Fair value - commitment date 680,276 274,449 - - 954,725 Fair value - mark to market adjustment 8,896 (17,009 ) 145 - (7,968 ) Derivative liabilities - June 30, 2023 $ 1,528,426 $ 837,293 $ 80,372 $ - $ 2,446,091 Fair value - mark to market adjustment prior to conversion or reclassification (105,790 ) 1,455 (45,207 ) - (149,542 ) Conversion of convertible promissory notes (1,422,636 ) - (35,165 ) - (1,457,801 ) Reclassification of warrants to equity - (838,748 ) - - (838,748 ) Recognition of contingent milestone liability - - - 2,117,142 2,117,142 Fair value - mark to market adjustment - - - 57,052 57,052 Derivative liabilities - September 30, 2023 $ - $ - $ - $ 2,174,194 $ 2,174,194 Bridge Shares Warrants Convertible Total Derivative liabilities - December 31, 2021 $ - $ - $ - $ - Fair value - commitment date 823,687 565,007 95,194 1,483,888 Fair value - mark to market adjustment 664 2,932 (2,595 ) 1,001 Derivative liabilities - June 30, 2022 $ 824,351 $ 567,939 $ 92,599 $ 1,484,889 Fair value - mark to market adjustment 1,352 25,869 (4,726 ) 22,495 Derivative liabilities - September 30, 2022 $ 825,703 $ 593,808 $ 87,873 $ 1,507,384
Schedule of Conversion Features in Convertible Promissory Notes	The assumptions used to perform the Monte-Carlo Simulation as of the respective commitment dates, as well as December 31, 2022 were as follows: Commitment Dates May 2023 May 2022 Stock price $ 5.30 $ 5.00 Volatility 115.1 % 99.7 % Expected term (in years) - Notes 0.99 1.00-1.03 Expected term (in years) - Warrants 4.99 5.00 Risk-free interest rate 4.80 % 2.76% - 2.84 % Dividend yield 0 % 0 % IPO probability (prior to note maturity date) 95 % 95 % Mark to Market December 31, 2022 Stock price $ 5.00 Volatility 101.9 % Expected term (in years) - Notes 0.39 - 0.41 Expected term (in years) - Warrants 4.39 Risk-free interest rate 4.06 % Dividend yield 0 % IPO probability (prior to note maturity date) 95 %

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
Share-Based Compensation (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Significant Assumptions Used in Determining the Fair Value of Options Granted	The following table summarizes the significant assumptions used in determining the fair value of options granted for the three and nine months ended September 30, 2023: 2023 Weighted-average grant date fair value $ 3.42 Risk-free interest rate 4.25% - 4.33 % Expected volatility 105.0% - 110.0 % Expected term (years) 3.18 - 3.76 Expected dividend yield 0.00 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
Commitments and Contingencies (Tables)	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis	Future minimum lease payments on a discounted and undiscounted basis under the Company’s operating lease are as follows: Undiscounted Discount rate 15.00 % 2023 (remaining three months) $ 13,992 2024 13,992 Thereafter - Total undiscounted minimum future payments 27,984 Imputed interest (1,184 ) Total operating lease payments 26,800 Short-term lease liabilities 26,800 Long-term lease liabilities $ -
Schedule of Other Information Related to our Operating Lease	Other information related to our operating lease is as follows: September 30, Weighted average remaining lease term (in years) 0.50 Weighted average discount rate 15.00 %

Nature of Operations (Details)

Nature of Operations (Details) - USD ($)			9 Months Ended
Nature of Operations (Details) - USD ($)	Jul. 14, 2023	Jul. 13, 2023	Sep. 30, 2023
Initial Public Offering [Member]
Nature of Operations (Details) [Line Items]
Initial public offering shares (in Shares)	1,415,095
Price per unit	$ 5.3
Net proceeds (in Dollars)	$ 6,454,325
Common stock of par value			$ 0.0001
Tradeable warrants [Member]
Nature of Operations (Details) [Line Items]
Price per unit			$ 0.01
Exercise price per share	$ 6.095
Purchase of shares (in Shares)		100,644	212,265
Non-tradeable warrants [Member]
Nature of Operations (Details) [Line Items]
Price per unit			$ 0.01
Exercise price per share	$ 6.36
Tradeable warrants expired team	5 years
Purchase of shares (in Shares)		100,644	212,265
Over-Allotment Option [Member]
Nature of Operations (Details) [Line Items]
Price per unit			$ 5.28
Purchase of shares (in Shares)			212,265
Representative Warrants [Member]
Nature of Operations (Details) [Line Items]
Price per unit			$ 5.83
Purchase of shares (in Shares)			84,906
Representative warrants exercisable term			5 years

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 02, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Consolidated owner percentage		100%		100%
Common shares issued (in Shares)	904,436
Significant customers, description				Significant customers represent any customer whose business makes up 10% of receivables or revenues. 100% of receivables as of September 30, 2023, consisting of two significant customers at 78% and 22%, are outstanding from significant customers. At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were outstanding from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers (100% for the three months ended September 30, 2022 consisting of three significant customers at 48%, 43%, and 9%). For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28% (100% for the nine months ended September 30, 2022, consisting of three customers at 65%, 29%, and 6% respectively).
Non-related party debt rate				0%		85%
Research and development costs expense		$ 263,703	$ 182,655	$ 591,569	$ 477,106
Issued common stock shares (in Shares)		525,000		525,000
Common stock shares as share-based payments (in Shares)				405,000
Unamortized deferred prepaid research and development costs				$ 2,834,148		$ 0
Share-based payments vested shares (in Shares)				513,000	0
Prepaid and other assets		$ 1,063,235		$ 1,063,235		$ 0
Australia Pty Ltd [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Proportional ownership percentage	87.53%
Australia Pty Ltd [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Proportional ownership percentage	96.61%
Trevally, LLC [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Issued common stock shares (in Shares)		120,000		120,000
Carmel, Milazzo & Feil LLP [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Issued common stock shares (in Shares)		100,000		100,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Liabilities Measured at Fair Value - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Liabilities:
Total	$ 2,174,194	$ 1,494,200
Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities		1,494,200
Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities	2,174,194
Level 1 [Member]
Liabilities:
Total
Level 1 [Member] \| Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities
Level 1 [Member] \| Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities
Level 2 [Member]
Liabilities:
Total
Level 2 [Member] \| Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities
Level 2 [Member] \| Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities
Level 3 [Member]
Liabilities:
Total	2,174,194	1,494,200
Level 3 [Member] \| Derivative Liabilities [Member]
Liabilities:
Promissory Notes (including accrued interest), at fair value
Derivative Liabilities		$ 1,494,200
Level 3 [Member] \| Derivative Liabilities [Member]
Liabilities:
Derivative Liabilities	$ 2,174,194

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Exchange Rates Along with Historical Rates Used in these Financial Statements - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
AUD [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate			$ 0.6428		$ 0.6805
AUD [Member] \| Average Exchange Rate [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate	$ 0.6545	$ 0.6837	0.6688	$ 0.7074
SGD [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate					$ 1.023	[1]
SGD [Member] \| Average Exchange Rate [Member]
Intercompany Foreign Currency Balance [Line Items]
Average Exchange Rate				$ 1.015

[1]Through 4/30/2022 (account closure date)

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Raw Material (API)	$ 350,362	$ 397,487
Packaging	73,391	97,486
Finished Goods	108,208	183,943
Clinical Trial Supplies	149,812	63,062
Total Inventory	681,773	741,978
Reserve for Expiring Inventory	(83,454)	(223,400)
Inventory, net	$ 598,319	$ 518,578

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property and Equipment [Abstract]
Depreciation expenses	$ 5,485	$ 6,901	$ 19,287	$ 20,747

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 150,025	$ 148,202
Accumulated depreciation	(146,189)	(126,902)
Property and Equipment, Net	3,836	21,300
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	132,911	132,911
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	14,084	12,261
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, at Cost	$ 3,030	$ 3,030

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
Intangible Assets (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Intangible Assets [Abstract]
Capitalized website development or related costs	$ 12,283	$ 0	$ 52,178	$ 0
Amortization expense	7,414	$ 1,831	20,606	$ 2,783
Capitalized patent expenses	$ 83,808		$ 83,808

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Abstract]
Patents	$ 174,833	$ 145,613
Website Development Costs	79,248	27,070
Intangible Assets, at Cost	254,081	172,683
Accumulated Amortization	(29,034)	(8,428)
Intangible Assets, Net	$ 225,047	$ 164,255

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs	Sep. 30, 2023 USD ($)
Patents [Member]
Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2023 (remaining three months)	$ 1,670
2024	6,681
2025	6,681
2026	6,681
Thereafter	55,656
Total	77,369
Website Development Costs [Member]
Intangible Assets (Details) - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]
2023 (remaining three months)	6,604
2024	26,416
2025	23,303
2026	3,974
Thereafter
Total	$ 60,297

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)				1 Months Ended	9 Months Ended
Stockholders' Equity (Details) - USD ($)	Sep. 30, 2023	Jul. 14, 2023	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2023	Jul. 25, 2023	Jul. 17, 2023	Jul. 13, 2023	Jul. 11, 2023	May 31, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022	Jun. 01, 2022	May 31, 2022	May 05, 2022
Stockholders' Equity [Line Items]
Price per share (in Dollars per share)														$ 5
Preferred stock shares authorized	1,000,000				1,000,000								1,000,000
Preferred stock shares, par value (in Dollars per share)	$ 0.0001				$ 0.0001								$ 0.0001
Common stock, shares issued		29,245					93,000	31,447		231,917					231,917
Preferred stock shares outstanding	78,803				78,803								0
Preferred stock shares issued	78,803				78,803								0
Percentage of cancelled shares issued													61%
Percentage of cancelled shares outstanding													61%
Exercise of warrants	31,447				31,447			31,447		151,991					151,991
Sale of stock price per share (in Dollars per share)	$ 23,496				$ 23,496
Common stock upon conversion		214,934
Common stock upon conversion		60,000				45,560
Exercise price of warrants (in Dollars per share)										$ 5.83					$ 5.83
Percentage of IPO price										110%					110%
Cash proceeds (in Dollars)	$ 1,131,771				$ 1,131,771
Dividends percentage					6%
Common Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, convertible shares						45,560
60P LLC [Member]
Stockholders' Equity [Line Items]
Common stock par value (in Dollars per share)														$ 0.0001
Common stock, shares issued	5,799,535				5,799,535
Common stock, shares outstanding	5,799,535				5,799,535
60 Degrees Pharmaceuticals, Inc. [Member]
Stockholders' Equity [Line Items]
Common stock par value (in Dollars per share)	$ 0.0001				$ 0.0001
Common stock shares authorized	150,000,000				150,000,000
Tradeable warrants [Member]
Stockholders' Equity [Line Items]
Exercise of warrants	93,000	60,000			93,000
Non-tradeable warrants [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued							93,000
Exercise of warrants	60,000				60,000
IPO [Member]
Stockholders' Equity [Line Items]
Common stock par value (in Dollars per share)	$ 0.0001				$ 0.0001
Price per share (in Dollars per share)		$ 5.3
Common stock, shares issued		1,415,095
Exercise of warrants										79,926					79,926
Sale of stock price per share (in Dollars per share)		$ 5.3
Net proceeds (in Dollars)		$ 6,454,325
Common stock upon conversion		383,908	1,108,337
Deferred compensation equity (in Dollars)		$ 155,000														$ 155,000
Common stock outstanding percentage			19.90%
Percentage of IPO price										90%					90%
IPO [Member] \| Common Stock Warrants [Member]
Stockholders' Equity [Line Items]
Exercise price of warrants (in Dollars per share)										$ 4.77					$ 4.77
Vendors [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued											1,443,000	1,443,000
Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, convertible shares	80,965				80,965	2,162
Preferred stock shares outstanding
Preferred stock shares issued	78,803				78,803
Preferred stock converted shares (in Dollars per share)	$ 100		$ 80,965		$ 100
Dividends percentage					19.90%
Preferred stock dividend outstanding	101,538
Description of Conversion term					The “Conversion Price” is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company’s IPO, or (c) the 10-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.
Series A Preferred Stock [Member] \| Common Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, convertible shares						2,162
Restricted Common Stock Shares [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued									40,000
Chief Executive Officer [Member]
Stockholders' Equity [Line Items]
Price per share (in Dollars per share)				$ 5
Purchase price (in Dollars)				$ 185,335
Chief Executive Officer [Member] \| Common Stock [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued				37,067
Stephen Toovey [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued									10,000
Charles Allen [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued									10,000
Cheryl Xu [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued									10,000
Paul Field [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued									10,000
Tyrone Miller [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued											192,101	192,101
Geoffrey S. Dow [Member]
Stockholders' Equity [Line Items]
Common stock, shares issued											1,258,899	1,258,899

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of Equity Classified Warrants - $ / shares			3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2023
Schedule of Equity-Classified Warrants [Abstract]
Number of Warrants, Total outstanding, June 30, 2023
Weighted Average Exercise Price, Total outstanding, June 30, 2023
Weighted Average Remaining Contractual Life (Years), Total outstanding, June 30, 2023	4 years 8 months 23 days
Number of Warrants, Reclassified from derivative liabilities	231,917		231,917
Weighted Average Exercise Price, Reclassified from derivative liabilities			$ 5.46
Weighted Average Remaining Contractual Life (Years), Reclassified from derivative liabilities			4 years 1 month 24 days
Number of Warrants, Granted			3,116,384
Weighted Average Exercise Price, Granted			$ 6.22
Weighted Average Remaining Contractual Life (Years), Granted			5 years
Number of Warrants, Exercised			(184,447)
Weighted Average Exercise Price, Exercised			$ 6.14
Weighted Average Remaining Contractual Life (Years), Exercised			5 years
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited
Number of Warrants, Expired
Weighted Average Exercise Price, Expired
Number of Warrants, Total outstanding, September 30, 2023	3,163,854		3,163,854
Weighted Average Exercise Price, Total outstanding, September 30, 2023	$ 6.17		$ 6.17
Weighted Average Remaining Contractual Life (Years), Total outstanding, September 30, 2023	4 years 8 months 23 days
Number of Warrants, Total exercisable, September 30, 2023	3,163,854		3,163,854
Weighted Average Exercise Price, Total exercisable, September 30, 2023	$ 6.17		$ 6.17
Weighted Average Remaining Contractual Life (Years), Total exercisable, September 30, 2023			4 years 8 months 23 days

Deferred Compensation (Details)

Deferred Compensation (Details) - USD ($)			1 Months Ended	12 Months Ended
Deferred Compensation (Details) - USD ($)	Jan. 11, 2023	May 05, 2022	Jun. 17, 2022	Dec. 31, 2022	Sep. 30, 2023	Jul. 14, 2023	Dec. 31, 2020
Deferred Compensation (Details) [Line Items]
Received consulting services							$ 100,000
Deferred cash		$ 60,000
Deferred compensation warrants		400,000
Cash component		100,000	$ 38,900
Equity compensation					$ 245,000
Shares issued (in Shares)					29,245
Deferred cash compensation			57,198
Accrued expenses			$ 12,500
Contingent deferred compensation, percentage			100%
Deferred compensation, common shares			$ 60,000
Deferred compensation, shares issued (in Shares)	65,000			65,000
Deferred compensation, per share (in Dollars per share)				$ 5
Subsequent agreement				$ 325,000
IPO [Member]
Deferred Compensation (Details) [Line Items]
Deferred compensation warrants			$ 10,000,000
Equity compensation		$ 155,000				$ 155,000
Shares issued (in Shares)						1,415,095

Debt (Details)

Debt (Details) - USD ($)							1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
Debt (Details) - USD ($)	Jan. 09, 2023	Nov. 04, 2022	Mar. 31, 2022	Jan. 01, 2022	May 14, 2020	Oct. 11, 2017	May 31, 2023	May 31, 2022	Mar. 31, 2022	Dec. 27, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	May 11, 2023	Apr. 30, 2023	Apr. 23, 2023	Mar. 31, 2023	Dec. 31, 2022	Apr. 24, 2019
Debt (Details) [Line Items]
Principal amount			$ 10,770,037		$ 150,000				$ 10,770,037
Debenture																					$ 3,000,000
Knight Loan amount																				$ 20,596,595
Promissory note issued amount						$ 750,000
Interest rate, per annum						10%
Maturity days									30 days
Excess fair value discount											$ 120,683		$ 120,683
Note and incurred costs													1,767
Amortization discount											3,869	$ 0	52,628	$ 0
Interest expense											4,944	29,429	66,558	85,242
Converted shares (in Shares)			214,934
Debt extinguishment gain													223,077
Original issue discount													$ 10,128,500
Debt issuance costs																					$ 2,100,000
Additional cash payments							$ 22,222	$ 8,472
Description of 2022 and 2023 bridge note													As a result of the completion of the IPO and as required under the terms of the 2022 and 2023 Bridge Notes, the Company issued the holders 303,982 shares of common stock, determined by the outstanding principal balance of each note divided by the IPO price. In addition, the Company made cash payments to the holders of the 2022 and 2023 Bridge Notes totaling $1,749,488 for the outstanding principal, accrued interest and Extension Payments (2022 Bridge Notes only), in full settlement of the outstanding debt obligations. The embedded derivative liability (conversion feature) was marked to market on the settlement date, and the Company recognized a debt extinguishment loss of $614,670 upon settlement, representing the difference between (i) the reacquisition price, consisting of cash and shares, and (ii) the net carrying value of the debt including associated derivative liabilities on the date of conversion.
Amortization of debt discounts													$ 669,148	821,154
Description of related party notes													As a result of the completion of the IPO and as required under the terms of the Related Party Notes, the entirety of the outstanding principal balance converted to 79,926 shares of common stock at a conversion rate equal to 80% of the IPO price, fully satisfying the Company’s obligations with respect to the principal amount. In addition, the Company made cash payments to the related party holders totaling $31,968 in full settlement of the outstanding accrued interest and Extension Payments. The Company recognized a final mark to market adjustment of the embedded derivative liability (conversion feature), and as a result, no gain or loss was recognized on the debt extinguishment.
Accumulated interest																				1,555,670
Gross proceeds													$ 6,454,325
Initial public offering discount, percentages													15%
Common stock outstanding, percentages													19.90%
Payment of milestones													$ 10,000,000
Regulatory advice value													$ 30,000
Cumulative dividend																			6%
Common stock ownership percentage											19.90%		19.90%
Equal royalty pay to lender, percentage				$ 3.5
Extinguishment Amount	$ 839,887										$ (391,593)		$ (1,231,480)
Description of knight debt conversion agreement													As a result of the completion of the IPO and as required under the terms of the Knight Debt Conversion Agreement, the cumulative outstanding principal as of March 31, 2022 converted to 1,108,337 shares of common stock (representing 19.9% ownership of the Company’s common stock after giving effect to the IPO). In addition, the entirety of the accumulated interest as of March 31, 2022 converted into 80,965 shares of Series A Preferred Stock at the conversion rate detailed above, in full satisfaction of the Company’s obligations with respect to the accumulated interest. Upon consummation of the IPO and under the terms of the Knight Debt Conversion Agreement, the Company became obligated to the contingent milestone payments and the accumulated Royalty discussed above, which value was included in the reacquisition price of the debt upon extinguishment. The Company recognized a final mark-to-market adjustment of $6,106,066 to adjust the Convertible Knight Loan to its fair value on the date of settlement, and as a result, no gain or loss was recognized on the debt extinguishment.
Unamortized original issue discount											0		$ 0							279,061
Annual interest rate					3.75%
Committed to monthly payments					$ 731
Interest payments		$ 731
Long-term debt, current maturities													8,772
Long-term liability											152,594		152,594							160,272
Current maturity																				2,750
Payment terms, balloon payment to be paid													32,383
Short term advance, received																$ 250,000	$ 50,000
Chief Executive Officer [Member]
Debt (Details) [Line Items]
Promissory notes face amount								$ 338,889
Original issue discount rate								10%
Original issue discount								$ 33,888
Debt issuance costs								34,289
Net proceeds								$ 270,711
Notes bear interest								6%
Default interest rate								15%
Face amount, percentage								20%
Fully vested warrants exercise price percentage								90%
Knight Therapeutics, Inc. [Member]
Debt (Details) [Line Items]
Principal amount										$ 6,309,823
Accrued interest										4,160,918
Debenture										$ 3,483,851
Annual interest rate																		15%
Debenture interest rate																		9%
Promissory Note [Member]
Debt (Details) [Line Items]
Interest rate						5%
2022 Bridge Notes [Member]
Debt (Details) [Line Items]
Promissory notes face amount								$ 888,889
Original issue discount rate								10%
Original issue discount								$ 88,889
Debt issuance costs								91,436
Net proceeds								$ 708,564
Notes bear interest								10%
Default interest rate								15%
Face amount, percentage								100%
Fully vested warrants exercise price percentage								110%
2023 Bridge Notes [Member]
Debt (Details) [Line Items]
Promissory notes face amount							$ 722,222
Original issue discount rate							10%
Original issue discount							$ 72,222
Debt issuance costs							95,000
Net proceeds							$ 555,000
Notes bear interest							10%
Default interest rate							15%
Face amount, percentage							100%
Fully vested warrants exercise price percentage							110%
Related Party Notes [Member]
Debt (Details) [Line Items]
Amortization of debt discounts													670,550	453,063
Knight Debt Conversion [Member]
Debt (Details) [Line Items]
Accumulated interest			$ 8,096,486						$ 8,096,486
Accumulated capitalized interest costs													100
Debenture [Member]
Debt (Details) [Line Items]
Amortized interest expense											13,696	$ 368,091	13,696	$ 368,091
Small Business Administration [Member]
Debt (Details) [Line Items]
Principal payments											161,366		161,366							$ 163,022
Forecast [Member] \| IPO [Member]
Debt (Details) [Line Items]
Gross proceeds															$ 7,000,000
Geoffrey S. Dow Revocable Trust [Member]
Debt (Details) [Line Items]
Short term advance, received																			$ 200,000
Short term advance, received													23,000
Tyrone Miller [Member]
Debt (Details) [Line Items]
Short term advance, received											$ 27,000		$ 27,000

Debt (Details) - Schedule of Pr

Debt (Details) - Schedule of Promissory Notes - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		$ 17,965,670
Promissory Notes (including accrued interest)
Less Current Maturities		16,855,887
Long Term Promissory Notes		1,109,783
Knight Therapeutics [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		16,319,986
Promissory Notes (including accrued interest)
Less Current Maturities		16,319,986
Long Term Promissory Notes
Note, Including Amendment [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		1,109,783
Promissory Notes (including accrued interest)
Less Current Maturities
Long Term Promissory Notes		1,109,783
Bridge Notes [Member]
Debt (Details) - Schedule of Promissory Notes [Line Items]
Promissory Notes (including accrued interest), at fair value		535,901
Promissory Notes (including accrued interest)
Less Current Maturities		535,901
Long Term Promissory Notes

Debt (Details) - Schedule of Br

Debt (Details) - Schedule of Bridge Notes and Related Party Notes - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2022
2022 Bridge Notes May 2022 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes	[1]		1 year
Interest rate			10%
Default interest rate			15%
Collateral			Unsecured
Conversion rate	[2]		2
Face amount of notes			$ 888,889
Less: unamortized debt discount			(407,555)
Add: accrued interest on promissory notes			54,567
Balance - June 30, 2023
Balance - December 31, 2022			$ 535,901
Related Party Notes May 2022 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes	[1]		1 year
Interest rate			6%
Default interest rate			15%
Collateral			Unsecured
Conversion rate	[2]		2
Face amount of notes			$ 338,889
Less: unamortized debt discount			(155,443)
Add: accrued interest on promissory notes			11,651
Balance - June 30, 2023
Balance - December 31, 2022			$ 195,097
2023 Bridge Notes May 2023 [Member]
Related Party Transaction [Line Items]
Maturity date of promissory notes	[1]		1 year
Interest rate			10%
Default interest rate			15%
Collateral			Unsecured
Conversion rate	[2]		2
Face amount of notes
Less: unamortized debt discount
Add: accrued interest on promissory notes
Balance - June 30, 2023
Balance - December 31, 2022

[1]earlier of 1 year from date of issuance or closing of IPO.[2]see discussion above for (a) and (b)

Debt (Details) - Schedule of Re

Debt (Details) - Schedule of Reconciliation of the Beginning and Ending Balances for the Convertible Knight Note - USD ($)	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Convertible Debt [Abstract]
Promissory Notes, at fair value begining	$ 23,539,996	$ 21,815,841
Fair value at modification date - January 9, 2023			21,520,650
Fair value - mark to market adjustment	(6,105,066)	1,064,849	(339,052)
Extinguishment of Promissory Notes	(17,434,930)
Accrued interest recognized		659,306	634,243
Promissory Notes, at fair value ending		$ 23,539,996	$ 21,815,841

Debt (Details) - Schedule of th

Debt (Details) - Schedule of the Knight Debenture - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of the Knight Debenture [Abstract]
Original Debenture		$ 3,000,000
Unamortized debt discount		(279,061)
Debenture Prior to Accumulated Interest		2,720,939
Accumulated Interest		1,555,670
Debenture		$ 4,276,609

Debt (Details) - Schedule of _2

Debt (Details) - Schedule of the Current Future Payment Obligations	Sep. 30, 2023 USD ($)
Schedule of the Current Future Payment Obligations [Abstract]
2023 (remaining three months)
2024
2025
2026
2027	2,804
Thereafter	147,196
Total	$ 150,000

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	9 Months Ended
Derivative Liabilities (Details) - USD ($)	Sep. 30, 2023	May 24, 2022	May 08, 2022
Derivative Liabilities (Details) [Line Items]
Net change in the fair of derivative liabilities	$ (95,324)
Net change in the fair value of derivative liabilities per share (in Dollars per share)	$ 23,496
2022 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Fair value on the commitment date amount		$ 1,483,888
2022 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Net proceeds received	$ 979,275
2023 Bridge Notes and warrants [Member]
Derivative Liabilities (Details) [Line Items]
Fair value on the commitment date amount			$ 954,725
Net proceeds received	$ 555,000

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Derivative Expense - USD ($)	May 08, 2023	May 24, 2022
Schedule of Derivative Expense [Abstract]
Fair value of derivative liabilities	$ 954,725	$ 1,483,888
Less: face amount of debt	(555,000)	(979,275)
Derivative expense	$ 399,725	$ 504,613

Derivative Liabilities (Detai_3

Derivative Liabilities (Details) - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis - USD ($)	3 Months Ended					6 Months Ended	9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Beginning	$ 2,446,091	$ 1,499,334		$ 1,494,200	$ 1,484,889		$ 1,494,200
Fair value - mark to market adjustment	57,052		$ (7,968)	5,134	22,495	$ 1,001
Derivative liabilities - Ending	2,174,194	2,446,091	2,446,091	1,499,334	1,507,384	1,484,889	2,174,194	$ 1,507,384
Fair value - mark to market adjustment prior to conversion or reclassification	(149,542)
Conversion of convertible promissory notes	(1,457,801)						(1,457,801)
Reclassification of warrants to equity	(838,748)						838,748
Recognition of contingent milestone liability	2,117,142						2,117,142
Fair value - commitment date		954,725				1,483,888
Bridge Shares [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Beginning	1,528,426	839,254		834,352	824,351		834,352
Fair value - mark to market adjustment			8,896	4,902	1,352	664
Derivative liabilities - Ending		1,528,426	1,528,426	839,254	825,703	824,351		825,703
Fair value - mark to market adjustment prior to conversion or reclassification	(105,790)
Conversion of convertible promissory notes	(1,422,636)						(1,422,636)
Fair value - commitment date		680,276				823,687
Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Beginning	837,293	579,853		578,164	567,939		578,164
Fair value - mark to market adjustment			(17,009)	1,689	25,869	2,932
Derivative liabilities - Ending		837,293	837,293	579,853	593,808	567,939		593,808
Fair value - mark to market adjustment prior to conversion or reclassification	1,455
Reclassification of warrants to equity	(838,748)
Fair value - commitment date		274,449				565,007
Convertible Notes Payable [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liabilities - Beginning	80,372	80,227		81,684	92,599		81,684
Fair value - mark to market adjustment			145	(1,457)	(4,726)	(2,595)
Derivative liabilities - Ending		$ 80,372	$ 80,372	$ 80,227	$ 87,873	92,599		$ 87,873
Fair value - mark to market adjustment prior to conversion or reclassification	(45,207)
Conversion of convertible promissory notes	(35,165)						(35,165)
Fair value - commitment date						$ 95,194
Contingent Milestone Payment [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value - mark to market adjustment	57,052
Derivative liabilities - Ending	2,174,194						2,174,194
Recognition of contingent milestone liability	$ 2,117,142						$ 2,117,142

Derivative Liabilities (Detai_4

Derivative Liabilities (Details) - Schedule of Conversion Features in Convertible Promissory Notes - $ / shares	1 Months Ended		12 Months Ended
	May 31, 2023	May 31, 2022	Dec. 31, 2022
Commitment Dates [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price (in Dollars per share)	$ 5.3	$ 5
Volatility	115.10%	99.70%
Expected term (in years) - Notes	11 months 26 days
Expected term (in years) - Warrants	4 years 11 months 26 days	5 years
Risk-free interest rate	4.80%
Dividend yield	0%	0%	0%
IPO probability (prior to note maturity date)	95%	95%	95%
Mark to Market [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price (in Dollars per share)			$ 5
Volatility			101.90%
Expected term (in years) - Warrants			4 years 4 months 20 days
Risk-free interest rate			4.06%
Minimum [Member] \| Commitment Dates [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years) - Notes		1 year
Risk-free interest rate		2.76%
Minimum [Member] \| Mark to Market [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years) - Notes			4 months 20 days
Maximum [Member] \| Commitment Dates [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years) - Notes		1 year 10 days
Risk-free interest rate		2.84%
Maximum [Member] \| Mark to Market [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years) - Notes			4 months 28 days

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax [Abstract]
Provision for income taxes	$ 63	$ 250	$ 189	$ 750

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)			3 Months Ended			9 Months Ended
Share-Based Compensation (Details) - USD ($)	Jul. 12, 2023	Jul. 11, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation (Details) [Line Items]
Share based compensation recognized expense (in Dollars)		$ 187,196
Issuance of shares		40,000
Share of aggregate stock option	607,924
Weighted average exercise price (in Dollars per share)			$ 5.46
Stock option awards (in Dollars)			$ 233,728		$ 0	$ 233,728	$ 0
Granted of aggregate shares	32,000
Share of vesting				0		8,000
IPO [Member]
Share-Based Compensation (Details) [Line Items]
Weighted average exercise price (in Dollars per share)	$ 4.75
2022 Plan [Memeber]
Share-Based Compensation (Details) [Line Items]
Shares available under the plan						238,601
Restricted Stock Units [Member]
Share-Based Compensation (Details) [Line Items]
Share of vesting			37,338			0

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of Significant Assumptions Used in Determining the Fair Value of Options Granted	9 Months Ended
	Sep. 30, 2023 $ / shares
Share-Based Compensation (Details) - Schedule of Significant Assumptions Used in Determining the Fair Value of Options Granted [Line Items]
Weighted-average grant date fair value (in Dollars per share)	$ 3.42
Expected dividend yield	0%
Minimum [Member]
Share-Based Compensation (Details) - Schedule of Significant Assumptions Used in Determining the Fair Value of Options Granted [Line Items]
Risk-free interest rate	4.25%
Expected volatility	105%
Expected term (years)	3 years 2 months 4 days
Maximum [Member]
Share-Based Compensation (Details) - Schedule of Significant Assumptions Used in Determining the Fair Value of Options Granted [Line Items]
Risk-free interest rate	4.33%
Expected volatility	110%
Expected term (years)	3 years 9 months 3 days

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)		3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Jul. 11, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies (Details) [Line Items]
Operating lease costs		$ 13,859	$ 12,974	$ 41,225	$ 38,921
Common stock value				$ 480,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares)				513,000	0
Exercisse price				$ 1,131,771
Contingent payments		43,581		43,581
Business Combination, Contingent Consideration, Liability		2,117,142		2,117,142
IPO [Member]
Commitments and Contingencies (Details) [Line Items]
Business Combination, Contingent Consideration, Liability		$ 10,000,000		10,000,000
Cheryl Xu [Member] \| Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				11,250
Common stock value	$ 10,000
Cheryl Xu [Member] \| Board of Directors Chairman [Member] \| Non-qualified Option [Member]
Commitments and Contingencies (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares)	9,434
Paul Field [Member] \| Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				11,250
Exercisse price	$ 5.3
Paul Field [Member] \| Board of Directors Chairman [Member] \| non-audit committee [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				1,250
Charles Allen [Member] \| Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				11,250
Common stock value	100
Charles Allen [Member] \| Board of Directors Chairman [Member] \| Audit Committee [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				2,000
Charles Allen [Member] \| Board of Directors Chairman [Member] \| Non-qualified Option [Member]
Commitments and Contingencies (Details) [Line Items]
Exercisse price	$ 5.3
Stephen Toovey [Member] \| Board of Directors Chairman [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				11,250
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares)	7,547
Stephen Toovey [Member] \| Board of Directors Chairman [Member] \| non-audit committee [Member]
Commitments and Contingencies (Details) [Line Items]
Cash compensation				$ 1,250
Stephen Toovey [Member] \| Restricted Stock [Member] \| Board of Directors Chairman [Member] \| Non-qualified Option [Member]
Commitments and Contingencies (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in Shares)	8,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Future Minimum Lease Payments on a Discounted and Undiscounted Basis	9 Months Ended
	Sep. 30, 2023 USD ($)
Schedule of Future Minimum Lease Payments On A Discounted and Undiscounted Basis [Abstract]
Discount rate	15%
2023 (remaining three months)	$ 13,992
2024	13,992
Thereafter
Total undiscounted minimum future payments	27,984
Imputed interest	(1,184)
Total operating lease payments	26,800
Short-term lease liabilities	26,800
Long-term lease liabilities

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of Other Information Related to our Operating Lease	Sep. 30, 2023
Schedule of Other Information Related to our Operating Lease [Abstract]
Weighted average remaining lease term (in years)	6 months
Weighted average discount rate	15%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Nov. 09, 2023	Nov. 01, 2023
Subsequent Events (Details) [Line Items]
Return the deposited funds	$ 820,000
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Total deposits amount	$ 419,755
Subsequent Event [Member] \| Bridge warrants [Member]
Subsequent Events (Details) [Line Items]
Closing bid price per shares (in Dollars per share)		$ 1